Journal of Clinical Psychiatry

Subject Index to Volume 61: January 2000 Through December 2000

Academic Highlights
Alzheimer's disease: translating neurochemical insights into clinical benefits. Oct 791–803
New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications? Apr 307–315
Novel antidepressant strategies to optimize outcome. Sept 686–696
Novel antipsychotic use in schizophrenia. Mar 223–232
Role of mirtazapine in the pharmacotherapy of depression. Aug 609–616
Scourge of EPS: have atypical antipsychotics solved the problem? Dec 955–962

Acetylcholine
Paying attention to your acetylcholine, part 1: structural organization of nicotine receptors [Brainstorms]. Stahl, Aug 547–548
Paying attention to your acetylcholine, part 2: the function of nicotinic receptors [Brainstorms]. Stahl, Sept 628–629

Adolescents
Bipolar disorder and attention-deficit/hyperactivity disorder in children and adolescents. Giedd, Suppl 9, 31–34
Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. McConville, Apr 252–260

Age
Underuse of antidepressants in major depression: prevalence and correlates in a national sample of young adults [CME]. Druss, Mar 234–237

Aggression
Use of sodium valproate in violent and aggressive behaviors: a critical review. Lindenmayer, Feb 123–128

Agitation
Antipsychotic treatment of psychosis and agitation in the elderly. Daniel, Suppl 14, 49–52
Emergency treatment of depression complicated by psychosis or agitation. Glick, Suppl 14, 43–48
Introduction: acute care of the agitated psychotic patient. Allen, Suppl 14, 3–4
Managing the agitated psychotic patient: a reappraisal of the evidence. Allen, Suppl 14, 11–20
Pathophysiology of agitation. Lindenmayer, Suppl 14, 5–10

Akathisia
Restlessness of respiration as a manifestation of akathisia: five case reports of respiratory akathisia. Hirose, Oct 737–741

Algorithm, Treatment
Algorithm for the treatment of schizophrenia in the correctional setting: the Forensic Algorithm Project. Buscema, Oct 767–783

Allergy
Allergy to tartrazine in psychotropic drugs. Bhatia, July 473–476

Alzheimer's Disease
Alzheimer's disease: translating neurochemical insights into clinical benefits [Academic Highlights]. Oct 791–803
Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease [letter]. Dallocchio, Jan 64
Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. Weiner, July 487–492
Metrifonate for Alzheimer's disease patients [letter]. Schneider; Raskind reply, Mar 218–219
New cholinesterase inhibitors for Alzheimer's disease, part 1: their similarities are different [Brainstorms]. Stahl, Oct 710–711
New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications? [Academic Highlights] Apr 307–315

Amantadine
Bupropion-amantadine–associated neurotoxicity [letter]. Trappler, Jan 61–62

Amphetamines
Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. Horrigan, June 414–417

Antidepressants see also specific drugs
Antidepressant treatment of posttraumatic stress disorder. Pearlstein, Suppl 7, 40–43
Approaches to the enhancement of patient adherence to antidepressant medication treatment. Delgado, Suppl 2, 6–9
Are all antidepressants the same? Möller, Suppl 6, 24–28
Blue genes and the mechanism of action of antidepressants [Brainstorms]. Stahl, March 164–165
Case for an individual approach to the treatment of depression. Healy, Suppl 6, 18–23
Clinical issues in long-term treatment with antidepressants. Zajecka, Suppl 2, 20–25
Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings. Gómez Gómez, Apr 285–289
Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study [CME]. Ghaemi, Oct 804–808
How fast are antidepressants? Gelenberg, Oct 712–721
Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. Frank, Jan 51–57
Management of nonresponse and intolerance: switching strategies. Fava, Suppl 2, 10–12
Modafinil augmentation of antidepressant treatment in depression. Menza, May 378–381
New approaches to the treatment of refractory depression. Fava, Suppl 1, 26–32
New indications for antidepressants. Schatzberg, Suppl 11, 9–17
Noradrenergic approaches to antidepressant therapy. Gorman, Suppl 1, 13–16
Norepinephrine involvement in antidepressant action. Frazer, Suppl 10, 25–30
Novel antidepressant strategies to optimize outcome [Academic Highlights]. Sept 686–696
Pharmacologic characteristics of ideal antidepressants in the 21st century. DeVane, Suppl 11, 4–8
Problems with currently available antidepressants. Gumnick, Suppl 10, 5–15
Racial variation in antidepressant treatment in a Medicaid population. Melfi, Jan 16–21
Sexual side effects of antidepressants. Rothschild, Suppl 11, 28–36
SIADH with multiple antidepressants in a geriatric patient [letter]. Blass, June 448–449
Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. Thase, July 466–472
Treatment of severe depression. Thase, Suppl 1, 17–25
Underuse of antidepressants in major depression: prevalence and correlates in a national sample of young adults [CME]. Druss, Mar 234–237
Weight gain and antidepressants. Fava, Suppl 11, 37–41

Antipsychotics see also specific drugs
Antipsychotic drug side effect issues in bipolar manic patients. Zarate, Suppl 8, 52–63
Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study. Zarate, Jan 33–38
Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Keck, Suppl 4, 33–38
Antipsychotic treatment of psychosis and agitation in the elderly. Daniel, Suppl 14, 49–52
Atypical antipsychotic medications in the psychiatric emergency service. Currier, Suppl 14, 21–26
Atypical antipsychotics for treatment of mixed depression and anxiety [letter]. Kaplan, May 388–389

Efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Keck, Suppl 3, 4–9
Expected incidence of tardive dyskinesia associated with atypical antipsychotics. Glazer, Suppl 4, 21–26
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. Glazer, Suppl 3, 16–21
Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum [CME]. Garver, Dec 964–972
High exposure to neuroleptics in bipolar patients: a retrospective review [CME]. Brotman, Jan 68–72
Hormonal side effects in women: typical versus atypical antipsychotic treatment. Dickson, Suppl 3, 10–15
Incidence studies of tardive dyskinesia associated with typical antipsychotics. Glazer, Suppl 4, 15–20
Introduction. Antipsychotic standard of care: redefining the definition of atypical antipsychotics. Casey, Suppl 3, 3
Introduction. Side effects of antipsychotic medications: physician's choice of medication and patient compliance. Meltzer, Suppl 8, 3–4
Is antipsychotic drug-induced weight gain associated with a favorable clinical response? [letter] Lamberti; Ganguli reply, Sept 678
Need for a new framework to understand the mechanism of all antipsychotics [letter]. Stip; Remington reply, May 387–388
New treatments for bipolar disorder: the role of atypical neuroleptic agents. Ghaemi, Suppl 14, 33–42
Novel antipsychotic use in schizophrenia [ACADEMIC HIGHLIGHTS]. Mar 223–232
Overview of side effects caused by typical antipsychotics. Arana, Suppl 8, 5–13
Patients with schizophrenia at risk for excessive antipsychotic dosing. Walkup, May 344–348
Polypharmacy of 2 atypical antipsychotics [letter]. Rhoads; Stahl reply, Sept 678–680
Recovery-oriented psychopharmacology: redefining the goals of antipsychotic treatment. Noordsy, Suppl 3, 22–29
Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. Glazer, Suppl 4, 15–20
Side effects of antipsychotics in the elderly. Masand, Suppl 8, 43–51
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Kinon, Nov 833–840
Weight gain and antipsychotic medication. Blackburn, Suppl 8, 36–41

Anxiety

Atypical antipsychotics for treatment of mixed depression and anxiety [letter]. Kaplan, May 388–389

Attention-Deficit/Hyperactivity Disorder

Bipolar disorder and attention-deficit/hyperactivity disorder in children and adolescents. Giedd, Suppl 9, 31–34
Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. Horrigan, June 414–417
Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. Schubiner, Apr 244–251

Augmentation

Augmentation strategies in depression 2000. Nelson, Suppl 2, 13–19
Modafinil augmentation of antidepressant treatment in depression. Menza, May 378–381

Behavioral Disorders

Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease [letter]. Dallocchio, Jan 64

Benzodiazepines

Memory impairment in those who attempted suicide by benzodiazepine overdose [CME]. Verwey, June 456–459
Prior benzodiazepine exposure and benzodiazepine treatment outcome. Rickels, June 409–413
Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. DeMartinis, Feb 91–94

Binge-Eating Disorder

Treatment of binge-eating disorder with topiramate: a clinical case series. Shapira, May 368–372

Biology

Biology of posttraumatic stress disorder. Yehuda, Suppl 7, 14–21
Lithium up-regulates the cytoprotective protein bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. Manji, Suppl 9, 82–96
What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy? Friedman, Suppl 7, 44–51

Bipolar Disorder

Antipsychotic drug side effect issues in bipolar manic patients. Zarate, Suppl 8, 52–63
Bipolar disorder and attention-deficit/hyperactivity disorder in children and adolescents. Giedd, Suppl 9, 31–34
Bipolar disorder: diagnostic challenges and treatment considerations. Evans, Suppl 13, 26–31
Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment. Juckel, Aug 585–593
Clinical factors associated with treatment noncompliance in euthymic bipolar patients. Colom, Aug 549–555
Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. Ciapparelli, May 329–334
Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study [CME]. Ghaemi, Oct 804–808
Difficulties in diagnosis and management of bipolar disorder: three case presentations. Brady, Suppl 13, 32–37
Double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Calabrese, Nov 841–850
Economic burden of bipolar disease. Woods, Suppl 13, 38–41
Efficacy of lithium in mania and maintenance therapy of bipolar disorder. Bowden, Suppl 9, 35–40
Ever-increasing pharmacopoeia for the management of patients with bipolar disorder. Nemeroff, Suppl 13, 19–25
Gender and bipolar illness [CME]. Hendrick, May 393–396
Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. Weiss, May 361–367
High exposure to neuroleptics in bipolar patients: a retrospective review [CME]. Brotman, Jan 68–72
Integration of pharmacotherapy and psychotherapy for bipolar disorder. Rothbaum, Suppl 9, 68–75
Introduction: fifty years of lithium use in the treatment of bipolar disorder. Nemeroff, Suppl 9, 3–4
Lithium up-regulates the cytoprotective protein bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. Manji, Suppl 9, 82–96
Longitudinal course of bipolar disorder. Suppes, Suppl 9, 23–30
Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. Rasgon, Mar 173–178
Naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. Guille, Sept 638–642
Nature of bipolar disorder. Manji, Suppl 13, 42–57
New treatments for bipolar disorder: the role of atypical neuroleptic agents. Ghaemi, Suppl 14, 33–42
Prevalence of overweight and obesity in bipolar patients. Elmslie, Mar 179–184
Psychosocial interventions for bipolar disorder. Craighead, Suppl 13, 58–64
Suicide and bipolar disorder. Jamison, Suppl 9, 47–51
Treatment guidelines: current and future management of bipolar disorder. Goldberg, Suppl 13, 12–18
Treatment of bipolar depression. Compton, Suppl 9, 57–67
Twelve-month outcome in bipolar patients with and without personality disorders. Dunayevich, Feb 134–139

Blepharospasm

Clozapine in the treatment of neuroleptic-induced blepharospasm: a report of 4 cases. Levin, Feb 140–143

Books Reviewed

Allen JG: *Coping With Trauma: A Guide to Self-Understanding*. Nizny, Dec 953–954
American Psychiatric Association. *Dangerous Sex Offenders: A Task Force Report of the American Psychiatric Association*. Bernet, Sept 683
American Society of Clinical Psychopharmacology, Inc.: *Model Psychopharmacology Curriculum for Psychiatric Residency Programs, Training Directors, and Teachers of Psychopharmacology*. Yank, Dec 952–953
Ban TA, Healy D, Shorter E (eds): *The Rise of Psychopharmacology and the Story of CINP*. Meltzer, Jan 65–66

Beitman BD, Yue D: *Learning Psychotherapy: A Time-Efficient, Research-Based, and Outcome-Measured Psychotherapy Training Program and Seminar Leader's Manual.* Nash, Nov 876–877
Brown D, Scheflin AW, Hammond DC: *Memory, Trauma Treatment, and the Law.* Bernet, Aug 605
Cassidy J, Shaver PR (eds): *Handbook of Attachment: Theory, Research, and Clinical Applications.* Garber, Oct 790
Chaleby KS, Racy J (eds): *Psychotherapy With the Arab Patient.* Kronfol, May 390–391
Cunningham Owens DG: *A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs.* Thompson, Nov 878
DuPont RL: *The Selfish Brain: Learning From Addiction.* Straumanis, June 454
Ebert MH, Loosen PT, Nurcombe B (eds): *Current Diagnosis and Treatment in Psychiatry.* Weissman SH, Dec 953
Finley JR, Lenz BS: *The Chemical Dependence Treatment Documentation Sourcebook.* Hubbard, June 452–453
Ford CV: *Lies! Lies!! Lies!!! The Psychology of Deceit.* Weiner, Aug 604
Gabbard GO (ed): *Countertransference Issues in Psychiatric Treatment (Review of Psychiatry Series, vol. 18).* Weissman SH, June 452
Galanter M, Kleber HD (eds): *The American Psychiatric Press Textbook of Substance Abuse Treatment, 2nd ed.* Dilts, Nov 878
Gatchel RJ, Turk DC (eds): *Psychosocial Factors in Pain: Clinical Perspectives.* Catron, Apr 305
Halbreich U, Montgomery SA (eds): *Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders.* Dunner, Sept 682
Hales RE, Yudofsky SC: *Essentials of Clinical Psychiatry Based on The American Psychiatric Press Textbook of Psychiatry, 3rd ed.* Crowder, Nov 877
Hales RE, Yudofsky SC, Talbott JA (eds): *The American Psychiatric Association Textbook of Psychiatry, 3rd ed.* Scully, Apr 306
Hargreaves WA, Shumway M, Hu T, Cuffel B: *Cost-Outcome Methods for Mental Health.* Fishel-Ingram, Apr 305–306
Hays S: *The Cultural Contradictions of Motherhood.* Franco, July 530–531
Hilty DM, Hales RE, Yudofsky SC. *Study Guide to Essentials of Clinical Psychiatry.* Crowder, Nov 877
Jacobs SC. *Traumatic Grief: Diagnosis, Treatment, and Prevention.* Levi, July 531–532
Janowsky DS (ed): *Psychotherapy: Indications and Outcomes.* Nash, May 390
Johnstone E, Humphreys M, Lang F, Lawrie S, Sandler R: *Schizophrenia: Concepts and Clinical Management.* Tsuang, Mar 221–222
Koenig HG (ed): *Handbook of Religion and Mental Health.* Hummel, Oct 789
Koran LM: *Obsessive-Compulsive and Related Disorders in Adults: A Comprehensive Clinical Guide.* Salomon, Aug 606–607
Lewis JM III, Blotcky MJ: *Child Therapy Concepts, Strategies, and Decision Making.* Fuchs, Aug 605–606
Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds): *Substance Abuse: A Comprehensive Textbook, 3rd ed.* Johnson, July 530
McCullough JP Jr: *Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy (CBASP).* Salomon, Sept 684
McGorry PD, Jackson HJ (eds): *The Recognition and Management of Early Psychosis: A Preventive Approach.* Garver, June 453
Miller LJ (ed): *Postpartum Mood Disorders.* Augenstein, May 391
Millon T: *Personality-Guided Therapy.* Lomax, June 453–454
Millon T, Davis R: *Personality Disorders in Modern Life.* Gabbard, Feb 148
Mondimore FM: *Bipolar Disorder: A Guide for Patients and Families.* Weinstein, Oct 789–790
Nicholi AM Jr (ed): *The Harvard Guide to Psychiatry, 3rd ed.* Alarcón, Sept 684–685
Okpaku SO (ed): *Clinical Methods in Transcultural Psychiatry.* Lin, Mar 220–221
Perry PJ, Alexander B, Liskow BI: *Psychotropic Drug Handbook, 7th ed.* Findling, Mar 222
Robinson RG: *The Clinical Neuropsychiatry of Stroke.* Lyketsos, Feb 147
Roth M, Huppert FA, Mountjoy CQ, Tym E: *Camdex-R: The Cambridge Examination for Mental Disorders of the Elderly, Revised.* Salzman, Apr 306
Rush AJ (ed): *Mood Disorders: Systematic Medication Management.* Metzger, Feb 147–148
Schreter RK, Scharfstein SS, Schreter CA (eds): *Managing Care, Not Dollars: The Continuum of Mental Health Services.* Ronis, Mar 220
Shaffer D, Lucas CP, Richters JE (eds): *Diagnostic Assessment in Child and Adolescent Psychopathology.* Sarles, Sept 682–683
Shea SC: *The Practical Art of Suicide Assessment: A Guide for Mental Health Professionals and Substance Abuse Counselors.* Joseph, Sept 683–684
Siegel DJ: *The Developing Mind: Toward a Neurobiology of Interpersonal Experience.* Tanguay, July 531
Simon RI: *Bad Men Do What Good Men Dream: A Forensic Psychiatrist Illuminates the Darker Side of Human Behavior.* Morenz, Aug 604–605
Speer DC: *Mental Health Outcome Evaluation.* Bickman, Aug 607–608
Spurlock J (ed): *Black Psychiatrists and American Psychiatry.* Elam, Jan 66
Tamminga CA (ed): *Schizophrenia in a Molecular Age: Review of Psychiatry, vol. 18.* Meltzer, Nov 877–878
Weller EB, Weller RA, Rooney MT, Fristad MA: *ChIPS: Children's Interview for Psychiatric Syndromes.* Poznanski and Pavuluri, Aug 606
Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis W, Kines M (eds): *DSM-IV Sourcebook, vol. 4.* Rader, Dec 952
Wilens TE: *Straight Talk About Psychiatric Medications for Kids.* Brooks BA, Jan 65
Yehuda R (ed): *Risk Factors for Posttraumatic Stress Disorder.* Miller MC, July 532

Borderline Personality Disorder
Childhood abuse and platelet tritiated-paroxetine binding in bulimia nervosa: implications of borderline personality disorder. Steiger, June 428–435
Brain
Overview of the mechanism of action of lithium in the brain: fifty-year update. Lenox, Suppl 9, 5–15
Brainstorms
Blue genes and the mechanism of action of antidepressants. Stahl, Mar 164–165
Blue genes and the monoamine hypothesis of depression. Stahl, Feb 77–78
Molecular neurobiology for practicing psychiatrists, part 5: how a leucine zipper can turn on genes: immediate-early genes activate late-gene expression in the brain. Stahl, Jan 7–8
New cholinesterase inhibitors for Alzheimer's disease, part 1: their similarities are different. Stahl, Oct 710–711
New cholinesterase inhibitors for Alzheimer's disease, part 2: illustrating their mechanisms of action. Stahl, Nov 813–814
New drug discovery in the postgenomic era: from genomics to proteomics. Stahl, Dec 894–895
Paying attention to your acetylcholine, part 1: structural organization of nicotinic receptors. Stahl, Aug 547–548
Paying attention to your acetylcholine, part 2: the function of nicotinic receptors. Stahl, Sept 628–629
Seven habits of highly effective psychopharmacologists: overview. Stahl, Apr 242–243
Seven habits of highly effective psychopharmacologists, part 2: begin with the end in mind. Stahl, May 327–328
Seven habits of highly effective psychopharmacologists, part 3: sharpen the saw with selective choices of continuing medical education programs. Stahl, June 401–402
Seven habits of highly effective psychopharmacologists, part 4: developing and implementing the vision. Stahl, July 464–465
Breastfeeding
Mood stabilizers during breastfeeding: a review. Chaudron, Feb 79–90
Serum valproate levels in 6 breastfeeding mother-infant pairs. Piontek, Mar 170–172
Brief Psychiatric Rating Scale
Brief Psychiatric Rating Scale as an acute inpatient outcome measurement tool: a pilot study. Varner, June 418–421
Bulimia Nervosa
Childhood abuse and platelet tritiated-paroxetine binding in bulimia nervosa: implications of borderline personality disorder. Steiger, June 428–435
Bupropion
Bupropion-amantadine–associated neurotoxicity [letter]. Trappler, Jan 61–62
Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. Nofzinger, Nov 858–862
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. Weihs, Mar 196–202

Bupropion-tranylcypromine combination for treatment-refractory depression [letter]. Pierre, June 450–451
Omission of bupropion as a recommended treatment for PTSD [letter]. Reeves; Foa reply, Oct 786
Buspirone
Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. DeMartinis, Feb 91–94
Carbamazepine
Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. Iwata, July 528–529
Lack of sertraline efficacy probably due to an interaction with carbamazepine [letter]. Khan, July 526–527
Cardiovascular Side Effects
Electrocardiographic abnormalities in patients treated with clozapine. Kang, June 441–446
Child Abuse
Childhood abuse and platelet tritiated-paroxetine binding in bulimia nervosa: implications of borderline personality disorder. Steiger, June 428–435
Children
Bipolar disorder and attention-deficit/hyperactivity disorder in children and adolescents. Giedd, Suppl 9, 31–34
Chlorpromazine
Clozapine versus chlorpromazine in geriatric patients [letter]. Honigfeld, Jan 63–64
Cholinesterase
New cholinesterase inhibitors for Alzheimer's disease, part 1: their similarities are different [BRAINSTORMS]. Stahl, Oct 710–711
New cholinesterase inhibitors for Alzheimer's disease, part 2: illustrating their mechanisms of action [BRAINSTORMS]. Stahl, Nov 813–814
Chronic Fatigue Syndrome
Randomized, double-blind, placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. Hickie, Sept 643–648
Citalopram
Citalopram and clozapine: potential drug interaction [letter]. Borba, Apr 301–302
Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. Keller, Dec 896–908
Lack of desipramine toxicity with citalopram [letter]. Ashton, Feb 144
Treatment of koro with citalopram [letter]. Hallak, Dec 951
Clinical Trials
Adverse events of fluoxetine: postmarketing compared with premarketing clinical trials [letter]. Musa, Nov 874
Clomipramine
Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. Iwata, July 528–529
Placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Ninan, Jan 47–50
Clozapine
Citalopram and clozapine: potential drug interaction [letter]. Borba, Apr 301–302
Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. Ciapparelli, May 329–334
Clozapine in the treatment of neuroleptic-induced blepharospasm: a report of 4 cases. Levin, Feb 140–143
Clozapine treatment in a population of adults with mental retardation. Antonacci, Jan 22–25
Clozapine versus chlorpromazine in geriatric patients [letter]. Honigfeld, Jan 63–64
Colon perforation and peritonitis associated with clozapine [letter]. Freudenreich, Dec 950–951
Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. Sharif, July 498–504
Electrocardiographic abnormalities in patients treated with clozapine. Kang, June 441–446
Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. Lu, Aug 594–599
Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Rosenheck, May 382–386
Naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. Guille, Sept 638–642
Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution [letter]. Teter, Nov 872–873
Review and management of clozapine side effects. Miller DD, Suppl 8, 14–19
Switching clozapine responders to olanzapine. Littrell, Dec 912–915
Treatment of primary cranial dystonia (Meige's syndrome) with clozapine [letter]. Sieche, Dec 949
Cognitive-Behavioral Therapy
Placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Ninan, Jan 47–50
Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. Thase, July 466–472
Comorbidity
Comorbidity of psychiatric disorders and posttraumatic stress disorder. Brady, Suppl 7, 22–32
Psychiatric care of patients with depression and comorbid substance use disorders [CME]. Montoya, Sept 698–705
Conduct Disorder
Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. Schubiner, Apr 244–251
Consensus Statements
Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 5, 60–66
Continuing Medical Education (CME)
Acute Care of the Agitated Psychotic Patient, Suppl 14, 1–55
Antipsychotic Standard of Care: Redefining the Definition of Atypical Antipsychotics, Suppl 3, 1–32
Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. Ghaemi, Oct 804–808
Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. Ritsner, Nov 880–889
Explanatory therapy in hypochondriasis. Fava, Apr 317–322
Fifty Years of Lithium Use in the Treatment of Bipolar Disorder, Suppl 9, 1–107
Gender and bipolar illness. Hendrick, May 393–396
Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. Garver, Dec 964–972
High exposure to neuroleptics in bipolar patients: a retrospective review. Brotman, Jan 68–72
Memory impairment in those who attempted suicide by benzodiazepine overdose. Verwey, June 456–459
New Strategies for Improving the Treatment of Depression, Suppl 11, 1–53
New Strategies for the Treatment of Posttraumatic Stress Disorder, Suppl 7, 1–55
New Trends in Treating Premenstrual Dysphoric Disorder, Suppl 12, 1–30
Predictors of the development of phobic avoidance. Katerndahl, Aug 618–623
Psychiatric care of patients with depression and comorbid substance use disorders. Montoya, Sept 698–705
Sensory phenomena in obsessive-compulsive disorder and Tourette's disorder. Miguel, Feb 150–156
Seven habits of highly effective psychopharmacologists, part 3: sharpen the saw with selective choices of continuing medical education programs [BRAINSTORMS]. Stahl, June 401–402
Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance, Suppl 8, 1–70
Understanding Depression and Its Treatment: Restoration of Chemical Balance or Augmentation of Social Functioning, Suppl 6, 1–32
Underuse of antidepressants in major depression: prevalence and correlates in a national sample of young adults. Druss, Mar 234–237
Update on Tardive Dyskinesia, Suppl 4, 1–60
Use of electroconvulsive therapy in a state hospital: a 10-year review. Sylvester, July 534–539
Corrections
Mirtazapine substitution in SSRI-induced sexual dysfunction. Gelenberg, May 356–360; Correction, Sept 681
Twelve-month outcome in bipolar patients with and without personality disorders. Dunayevich, Feb 134–139; Correction, July 529
Corticosteroids
Recurrent cases of corticosteroid-induced mood disorder: clinical characteristics and treatment. Wada, Apr 261–267
Costs of Medical Care
Economic burden of bipolar disease. Woods, Suppl 13, 38–41
One-year costs of second-line therapies for depression. Sullivan, Apr 290–298

Delirium
Zolpidem-related delirium: a case report [letter]. Freudenreich, June 449–450
Depression
Are all antidepressants the same? Möller, Suppl 6, 24–28
Association between premenstrual syndrome and depression [letter]. Soares; Roca reply, Sept 677–678
Atypical antipsychotics for treatment of mixed depression and anxiety [letter]. Kaplan, May 388–389
Augmentation strategies in depression 2000. Nelson, Suppl 2, 13–19
Blue genes and the monoamine hypothesis of depression. Stahl, Feb 77–78
Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. Nofzinger, Nov 858–862
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. Weihs, Mar 196–202
Bupropion-tranylcypromine combination for treatment-refractory depression [letter]. Pierre, June 450–451
Case for an individual approach to the treatment of depression. Healy, Suppl 6, 18–23
Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. Keller, Dec 896–908
Clinical efficacy of reboxetine in major depression. Schatzberg, Suppl 10, 31–38
Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings. Gómez Gómez, Apr 285–289
Depression: the case for a monoamine deficiency. Delgado, Suppl 6, 7–11
Double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. Newhouse, Aug 559–568
Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Wagner, June 436–440
Effects of light therapy on suicidal ideation in patients with winter depression. Lam, Jan 30–32
Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. Beasley, Oct 722–728
Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. Suri, Dec 942–946
Efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. Schmidt, Nov 851–857
Emergency treatment of depression complicated by psychosis or agitation. Glick, Suppl 14, 43–48
Enhancing pharmacologic effects in the treatment of depression in women. Kornstein, Suppl 11, 18–27
Evidence for a biochemical lesion in depression. Leonard, Suppl 6, 12–17
Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Fava, Nov 863–867
Gold versus silver: the issue of functional versus symptomatic recovery in depression [letter]. Pradhan; Stahl reply, June 447–448
History and evolution of the monoamine hypothesis of depression. Hirschfeld, Suppl 6, 4–6
Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. Frank, Jan 51–57
Introduction: new strategies for improving the treatment of depression. Dunner, Suppl 11, 3
Introduction: optimizing treatment outcome in depression. Fava, Suppl 2, 4–5
Introduction. Spectrum of depression: new treatment approaches. Gorman, Suppl 1, 3–4
Introduction. Understanding depression and its treatment: restoration of chemical balance or creation of conditions promoting recovery? Montgomery, Suppl 6, 3
Lithium in unipolar depression and the prevention of suicide. Coppen, Suppl 9, 52–56
Mirtazapine compared with paroxetine in major depression. Benkert, Sept 656–663
Modafinil augmentation of antidepressant treatment in depression. Menza, May 378–381
New approaches to the treatment of refractory depression. Fava, Suppl 1, 26–32
New strategies for treating chronic depression. Kocsis, Suppl 11, 42–45
Norepinephrine dysfunction in depression. Anand, Suppl 10, 16–24
One-year costs of second-line therapies for depression. Sullivan, Apr 290–298
Paroxetine levels in postpartum depressed women, breast milk, and infant serum. Misri, Nov 828–832
Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. Fredman, June 403–408
Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. Claxton, Dec 928–932
Personality changes in adult subjects with major depressive disorder or obsessive-compulsive disorder treated with paroxetine. Brody, May 349–355
Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. McGrath, July 518–524
Psychiatric care of patients with depression and comorbid substance use disorders. Montoya, Sept 698–705
Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Mehtonen, Feb 95–100
Reboxetine treatment of depression in Parkinson's disease [letter]. Lemke, Nov 872
Role of mirtazapine in the pharmacotherapy of depression [ACADEMIC HIGHLIGHTS]. Aug 609–616
Role of norepinephrine in depression. Delgado, Suppl 1, 5–12
Social functioning and the treatment of depression. Weissman MM, Suppl 1, 33–38
Social functioning in depression: a review. Hirschfeld, Apr 268–275
SSRI-TCA combination in the treatment of resistant depression [letter]. Terao, July 529
Treatment issues related to sleep and depression. Thase, Suppl 11, 46–50
Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. Rothenhäusler, Oct 750–755
Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. Thase, July 466–472
Treatment of severe depression. Thase, Suppl 1, 17–25
Underuse of antidepressants in major depression: prevalence and correlates in a national sample of young adults [CME]. Druss, Mar 234–237
Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Zanardi, Jan 26–29
Venlafaxine versus sertraline for major depressive disorder [letter]. Wise, Nov 873–874
Desipramine
Lack of desipramine toxicity with citalopram [letter]. Ashton, Feb 144
Dextroamphetamine
Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Wagner, June 436–440
Diet
Clarifying the safety of the MAOI diet and pizza [letter]. Feinberg; Shulman reply, Feb 145–146
Divalproex see Valproate
Donepezil
Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease [letter]. Dallocchio, Jan 64
Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. Weiner, July 487–492
Dopamine
Depression: the case for a monoamine deficiency. Delgado, Suppl 6, 7–11
Drug Administration Schedule
Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. Feifel, Dec 909–911
Drug Safety Surveillance Project
Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. Stübner, Aug 569–574
Drugs, Nonprescription
Adverse neuropsychiatric reactions to herbal and over-the-counter "antidepressants." Pies, Nov 815–820
Dyskinesia
Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Keck, Suppl 4, 33–38

Expected incidence of tardive dyskinesia associated with atypical antipsychotics. Glazer, Suppl 4, 21–26
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. Glazer, Suppl 3, 16–21
Introduction: update on tardive dyskinesia. Casey, Suppl 4, 3–4
Is melatonin treatment effective for tardive dyskinesia? Shamir, Aug 556–558
Multiple rib fractures secondary to severe tardive dystonia and respiratory dyskinesia [letter]. Leung, Mar 215–216
Prevalence of spontaneous dyskinesia in schizophrenia. Fenton, Suppl 4, 10–14
Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. Glazer, Suppl 4, 15–20
Tardive dyskinesia in older patients. Jeste, Suppl 4, 27–32
Tardive dyskinesia: pathophysiology and animal models. Casey, Suppl 4, 5–9
Treatment of tardive dyskinesia and tardive dystonia. Simpson, Suppl 4, 39–44
Update on legal issues associated with tardive dyskinesia. Slovenko, Suppl 4, 45–57

Dysthymia
Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. Ravindran, Nov 821–827

Dystonia
Multiple rib fractures secondary to severe tardive dystonia and respiratory dyskinesia [letter]. Leung, Mar 215–216
Treatment of primary cranial dystonia (Meige's syndrome) with clozapine [letter]. Sieche, Dec 949
Treatment of tardive dyskinesia and tardive dystonia. Simpson, Suppl 4, 39–44

Egypt
Prodromal symptoms of relapse in a sample of Egyptian schizophrenic patients. Okasha, Oct 729–736

Elderly
Antipsychotic treatment of psychosis and agitation in the elderly. Daniel, Suppl 14, 49–52
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. Weihs, Mar 196–202
Clozapine versus chlorpromazine in geriatric patients [letter]. Honigfeld, Jan 63–64
Double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. Newhouse, Aug 559–568
Epidemiology, etiology, and treatment of geriatric mania. McDonald, Suppl 13, 3–11
Low-dose lithium augmentation of divalproex in geriatric mania [letter]. Goldberg, Apr 304
SIADH with multiple antidepressants in a geriatric patient [letter]. Blass, June 448–449
Side effects of antipsychotics in the elderly. Masand, Suppl 8, 43–51
Tardive dyskinesia in older patients. Jeste, Suppl 4, 27–32

Electroconvulsive Therapy
Use of electroconvulsive therapy in a state hospital: a 10-year review [CME]. Sylvester, July 534–539

Emergency Psychiatry
Atypical antipsychotic medications in the psychiatric emergency service. Currier, Suppl 14, 21–26
Emergency treatment of depression complicated by psychosis or agitation. Glick, Suppl 14, 43–48

Ephedrine
Olanzapine-induced urinary incontinence: treatment with ephedrine [letter]. Vernon, Aug 601–602

Epidemiology
Posttraumatic stress disorder: epidemiology and health-related considerations. Hidalgo, Suppl 7, 5–13

Epilepsy
Possible connection between panic disorder and epilepsy [letter]. Weilburg; Roy-Byrne reply, Aug 602

Estradiol
Positive treatment effect of estradiol in postpartum psychosis: a pilot study. Ahokas, Mar 166–169

Extrapyramidal Side Effects
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. Glazer, Suppl 3, 16–21
Scourge of EPS: have atypical antipsychotics solved the problem? [Academic Highlights] Dec 955–962

Eye Movement Desensitization and Reprocessing (EMDR)
EMDR for treatment of PTSD [letters]. Peterson, Smyth; Foa reply, Oct 784–785
Further discussion of EMDR for treatment of PTSD [letter]. Figley; Foa reply, Oct 785–786

Family
Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. Rosenheck, Sept 671–676
Texas Medication Algorithm Project patient and family education program: a consumer guided initiative. Toprac, July 477–486

Fluoxetine
Adverse events of fluoxetine: postmarketing compared with premarketing clinical trials [letter]. Musa, Nov 874
Case report of serotonin syndrome associated with combined nefazodone and fluoxetine [letter]. Smith, Feb 146
Double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. Newhouse, Aug 559–568
Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. Beasley, Oct 722–728
Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. Suri, Dec 942–946
Efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. Schmidt, Nov 851–857
Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Fava , Nov 863–867
Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. Claxton, Dec 928–932
Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. McGrath, July 518–524

Fluvoxamine
Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. Lu, Aug 594–599
Sexual dysfunction on fluvoxamine therapy [letter]. Laird; Nafziger reply, Jan 62–63
Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Zanardi, Jan 26–29

Forensic Algorithm Project
Algorithm for the treatment of schizophrenia in the correctional setting: the Forensic Algorithm Project. Buscema, Oct 767–783

Gabapentin
Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease [letter]. Dallocchio, Jan 64

Gender
Gender and bipolar illness [CME]. Hendrick, May 393–396
Gender difference in severity of schizophrenia [letter]. King, Jan 61

Generalized Anxiety Disorder
Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. DeMartinis, Feb 91–94
WATCHERS: recognizing generalized anxiety disorder [letter]. Berber, June 447

Genetics
Genetic studies of panic disorder: a review. van den Heuvel, Oct 756–766
Implications of genetic studies of major mood disorders for clinical practice. Duffy, Sept 630–637
New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications? [Academic Highlights] Apr 307–315

Geriatric Psychiatry see Elderly

Gilbert's Syndrome see Hyperbilirubinemia

Gilles de la Tourette's Disorder see Tourette's Disorder

Haloperidol
Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Brook, Dec 933–941
Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. Rosenheck, May 382–386

Health Services
Posttraumatic stress disorder: epidemiology and health-related considerations. Hidalgo, Suppl 7, 5–13

Herbal Medicine
Adverse neuropsychiatric reactions to herbal and over-the-counter "antidepressants." Pies, Nov 815–820

Hormones
Hormonal side effects in women: typical versus atypical antipsychotic treatment. Dickson, Suppl 3, 10–15

Hospitalization
Measuring patient symptom change on rural psychiatry units: utility of the Symptom Checklist-90 Revised. Ronan, July 493–497

Human Immunodeficiency Virus
Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. Wagner, June 436–440
Hyperbilirubinemia
Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). Miyaoka, Nov 868–871
Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome): three case reports [letter]. Miyaoka, Apr 299–300
Hypochondriasis
Explanatory therapy in hypochondriasis [CME]. Fava, Apr 317–322
Interictal Psychoses
Treatment of the interictal psychoses. Blumer, Feb 110–122
Interpersonal Psychotherapy
Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. Frank, Jan 51–57
Journal of Clinical Psychiatry
Millenial thanks [editorial]. Gelenberg, Jan 4–6
Physicians Postgraduate Press in the 21st Century [publisher's note]. Shelton, Jan 3
Special thanks [letter]. Gelenberg, Apr 299
Kleine-Levin Syndrome
Treatment of Kleine-Levin syndrôme: melatonin on the starting block [letter]. Kornreich, Mar 215
Koro
Treatment of koro with citalopram [letter]. Hallak, Dec 951
Lamotrigine
Double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Calabrese, Nov 841–850
Law
Update on legal issues associated with tardive dyskinesia. Slovenko, Suppl 4, 45–57
Levofloxacin
Severe lithium toxicity induced by combined levofloxacin administration [letter]. Takahashi, Dec 949–950
Light Therapy see Phototherapy
Lithium
Effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia [letter]. Martín, Dec 948
Efficacy of lithium in mania and maintenance therapy of bipolar disorder. Bowden, Suppl 9, 35–40
Increased lithium concentrations reported in patients treated with sulindac [letter]. Jones, July 527–528
Introduction: fifty years of lithium use in the treatment of bipolar disorder. Nemeroff, Suppl 9, 3–4
In vivo imaging of the pharmacodynamics and pharmacokinetics of lithium. Kilts, Suppl 9, 41–46
Lithium in unipolar depression and the prevention of suicide. Coppen, Suppl 9, 52–56
Lithium up-regulates the cytoprotective protein bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. Manji, Suppl 9, 82–96
Low-dose lithium augmentation of divalproex in geriatric mania [letter]. Goldberg, Apr 304
Optimizing lithium treatment. Dunner, Suppl 9, 76–81
Overview of the mechanism of action of lithium in the brain: fifty-year update. Lenox, Suppl 9, 5–15
Psychopharmacologic specificity of the lithium ion: origins and trajectory. Soares, Suppl 9, 16–22
Reduced suicide risk during lithium maintenance treatment. Tondo, Suppl 9, 97–104
Severe lithium toxicity induced by combined levofloxacin administration [letter]. Takahashi, Dec 949–950
Mania
Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study. Zarate, Jan 33–38
Epidemiology, etiology, and treatment of geriatric mania. McDonald, Suppl 13, 3–11
Low-dose lithium augmentation of divalproex in geriatric mania [letter]. Goldberg, Apr 304
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. Aubry, Sept 649–655
Subtyping micromanic episodes [letter]. Prosnick, Feb 144–145
Masturbation
Inappropriate masturbation and schizophrenia [letter]. Brooks JO, June 451
Mechanical Ventilation
Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. Rothenhäusler, Oct 750–755
Medicaid
Racial variation in antidepressant treatment in a Medicaid population. Melfi, Jan 16–21
Medical Illness
Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. Rothenhäusler, Oct 750–755
Melancholia
Diagnosing melancholia [letter]. Chelminski, Nov 874–875
Melatonin
Is melatonin treatment effective for tardive dyskinesia? Shamir, Aug 556–558
Melatonin improves sleep quality of patients with chronic schizophrenia. Shamir, May 373–377
Treatment of Kleine-Levin syndrome: melatonin on the starting block [letter]. Kornreich, Mar 215
Men
Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. Thase, July 466–472
Mental Retardation
Clozapine treatment in a population of adults with mental retardation. Antonacci, Jan 22–25
Metabolism
Childhood abuse and platelet tritiated-paroxetine binding in bulimia nervosa: implications of borderline personality disorder. Steiger, June 428–435
Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer [letter]. Güzey, Aug 600–601
Methylphenidate
Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. Rothenhäusler, Oct 750–755
Metrifonate
Metrifonate for Alzheimer's disease patients [letter]. Schneider; Raskind reply, Mar 218–219
Mirtazapine
Mirtazapine compared with paroxetine in major depression. Benkert, Sept 656–663
Mirtazapine substitution in SSRI-induced sexual dysfunction. Gelenberg, May 356–360
Role of mirtazapine in the pharmacotherapy of depression [ACADEMIC HIGHLIGHTS]. Aug 609–616
Moclobemide
Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. Kennedy, Apr 276–281
Randomized, double-blind, placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. Hickie, Sept 643–648
Modafinil
Modafinil augmentation of antidepressant treatment in depression. Menza, May 378–381
Monoamine Oxidase Inhibitors
Clarifying the safety of the MAOI diet and pizza [letter]. Feinberg; Shulman reply, Feb 145–146
Mood
Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Keck, Suppl 4, 33–38
Clinical predictors of acute response with quetiapine in psychotic mood disorders. Zarate, Mar 185–189
Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients [CME]. Ritsner, Nov 880–889
Divalproex sodium in substance abusers with mood disorder. Albanese, Dec 916–921
Implications of genetic studies of major mood disorders for clinical practice. Duffy, Sept 630–637
Increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. Frye, Jan 9–15
Mood stabilizers during breastfeeding: a review Chaudron, Feb 79–90
Recurrent cases of corticosteroid-induced mood disorder: clinical characteristics and treatment. Wada, Apr 261–267
Nefazodone
Case report of serotonin syndrome associated with combined nefazodone and fluoxetine [letter]. Smith, Feb 146
Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study. Coleman, Apr 282–284
Nefazodone-associated subjective complaints of burning sensations [letter]. Lerner, Mar 216–217

Nefazodone in patients with treatment-refractory posttraumatic stress disorder. Zisook, Mar 203–208

Neurobiology

Molecular neurobiology for practicing psychiatrists, part 5: how a leucine zipper can turn on genes: immediate-early genes activate late-gene expression in the brain [BRAINSTORMS]. Stahl, Jan 7–8

Neurotoxicity

Bupropion-amantadine–associated neurotoxicity [letter]. Trappler, Jan 61–62

Neutropenia

Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution [letter]. Teter, Nov 872–873

Noncompliance

Clinical factors associated with treatment noncompliance in euthymic bipolar patients. Colom, Aug 549–555

Norepinephrine

Depression: the case for a monoamine deficiency. Delgado, Suppl 6, 7–11

Evidence for a biochemical lesion in depression. Leonard, Suppl 6, 12–17

History and evolution of the monoamine hypothesis of depression. Hirschfeld, Suppl 6, 4–6

Introduction. Norepinephrine: neurotransmitter for the millennium. Nemeroff, Suppl 10, 3–4

Noradrenergic approaches to antidepressant therapy. Gorman, Suppl 1, 13–16

Norepinephrine dysfunction in depression. Anand, Suppl 10, 16–24

Norepinephrine involvement in antidepressant action. Frazer, Suppl 10, 25–30

Role of norepinephrine in depression. Delgado, Suppl 1, 5–12

Obsessive-Compulsive Disorder

Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. Iwata, July 528–529

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. Koran, July 514–517

Open-label trial of St. John's wort (*Hypericum perforatum*) in obsessive-compulsive disorder. Taylor, Aug 575–578

Personality changes in adult subjects with major depressive disorder or obsessive-compulsive disorder treated with paroxetine. Brody, May 349–355

Relationship between types and severity of repetitive behaviors in Gilles de la Tourette's disorder and obsessive-compulsive disorder. Cath, July 505–513

Sensory phenomena in obsessive-compulsive disorder and Tourette's disorder. Miguel, Feb 150–156

Olanzapine

Adverse events related to olanzapine. Conley, Suppl 8, 26–30

Effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia [letter]. Martín, Dec 948

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. Melkersson, Oct 742–749

Naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. Guille, Sept 638–642

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. Koran, July 514–517

Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution [letter]. Teter, Nov 872–873

Olanzapine-induced urinary incontinence: treatment with ephedrine [letter]. Vernon, Aug 601–602

Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. Aubry, Sept 649–655

Safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO study). Gómez, May 335–343

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Kinon, Nov 833–840

Switching clozapine responders to olanzapine. Littrell, Dec 912–915

Outcome

Brief Psychiatric Rating Scale as an acute inpatient outcome measurement tool: a pilot study. Varner, June 418–421

Measuring outcome in posttraumatic stress disorder. Shalev, Suppl 5, 33–39

Panic

Comparison of persons with early- versus late-onset panic attacks. Katerndahl, June 422–427

Genetic studies of panic disorder: a review. van den Heuvel, Oct 756–766

Possible connection between panic disorder and epilepsy [letter]. Weilburg; Roy-Byrne reply, Aug 602

Sertraline treatment of panic disorder: response in patients at risk for poor outcome. Pollack, Dec 922–927

Paraphilias

Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. Kafka, Sept 664–670

Parkinson's Disease

Reboxetine treatment of depression in Parkinson's disease [letter]. Lemke, Nov 872

Paroxetine

Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. Kennedy, Apr 276–281

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. Weihs, Mar 196–202

Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Fava , Nov 863–867

Mirtazapine compared with paroxetine in major depression. Benkert, Sept 656–663

Paroxetine levels in postpartum depressed women, breast milk, and infant serum. Misri, Nov 828–832

Personality changes in adult subjects with major depressive disorder or obsessive-compulsive disorder treated with paroxetine. Brody, May 349–355

Patient Care

Approaches to the enhancement of patient adherence to antidepressant medication treatment. Delgado, Suppl 2, 6–9

Patient Education

Texas Medication Algorithm Project patient and family education program: a consumer-guided initiative. Toprac, July 477–486

Periodic Limb Movements

Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. Nofzinger, Nov 858–862

Personality Disorders

Twelve-month outcome in bipolar patients with and without personality disorders. Dunayevich, Feb 134–139

Pharmacokinetics

Free drug fraction versus free drug concentration [letter]. Pies; DeVane reply, June 449

In vivo imaging of the pharmacodynamics and pharmacokinetics of lithium. Kilts, Suppl 9, 41–46

Pharmacotherapy

Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. Davidson, Suppl 5, 52–56

Phenomenology

Misuse of the term *phenomenology* [letter]. Schwartz, Apr 303–304

Phobia

Predictors of the development of phobic avoidance. Katerndahl, Aug 618–623

Phototherapy

Effects of light therapy on suicidal ideation in patients with winter depression. Lam, Jan 30–32

Pisa Syndrome

Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. Stübner, Aug 569–574

Pleurothotonus see Pisa Syndrome

Polycystic Ovary Syndrome

Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. Rasgon, Mar 173–178

Polypharmacotherapy

Increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. Frye, Jan 9–15

Posttraumatic Stress Disorder

α_1-Adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. Raskind, Feb 129–133

Antidepressant treatment of posttraumatic stress disorder. Pearlstein, Suppl 7, 40–43

Biology of posttraumatic stress disorder. Yehuda, Suppl 7, 14–21

Comorbidity of psychiatric disorders and posttraumatic stress disorder. Brady, Suppl 7, 22–32

Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 5, 60–66

EMDR for treatment of PTSD [letters]. Peterson, Smyth; Foa reply, Oct 784–785
Further discussion of EMDR for treatment of PTSD [letter]. Figley; Foa reply, Oct 785–786
Introduction: focus on posttraumatic stress disorder. Ballenger, Suppl 5, 3
Introduction: new strategies for the treatment of posttraumatic stress disorder. Davidson, Suppl 7, 3–4
Measuring outcome in posttraumatic stress disorder. Shalev, Suppl 5, 33–39
Nefazodone in patients with treatment-refractory posttraumatic stress disorder. Zisook, Mar 203–208
Omission of bupropion as a recommended treatment for PTSD [letter]. Reeves, Oct 786
Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. Davidson, Suppl 5, 52–56
Posttraumatic residues of captivity: a follow-up of Israeli ex-prisoners of war. Neria, Jan 39–46
Posttraumatic stress disorder: a model of the longitudinal course and the role of risk factors. McFarlane, Suppl 5, 15–20
Posttraumatic stress disorder: epidemiology and health-related considerations. Hidalgo, Suppl 7, 5–13
Posttraumatic stress disorder: psychological factors and psychosocial interventions. Hembree, Suppl 7, 33–39
Posttraumatic stress disorder: the burden to the individual and to society. Kessler, Suppl 5, 4–12
Psychobiology of posttraumatic stress disorder. Nutt, Suppl 5, 24–29
Psychodynamic psychotherapy for PTSD [letters]. Plakun, Saporta; Foa reply, Oct 787–788
Psychosocial treatment of posttraumatic stress disorder. Foa, Suppl 5, 43–48
What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy? Friedman, Suppl 7, 44–51

Prazosin

α_1-Adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. Raskind, Feb 129–133

Prediction

Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. McGrath, July 518–524
Predictors of response to sertraline treatment of severe premenstrual syndromes. Freeman, Aug 579–584
Predictors of the development of phobic avoidance. Katerndahl, Aug 618–623

Premenstrual Disorders

Association between premenstrual syndrome and depression [letter]. Soares; Roca reply, Sept 677–678
History, evolution, and diagnosis of premenstrual dysphoric disorder. Endicott, Suppl 12, 5–8
Introduction: new trends in treating premenstrual dysphoric disorder. Cohen, Suppl 12, 3–4
Non-antidepressant treatment of premenstrual syndrome. Pearlstein, Suppl 12, 22–27
Predictors of response to sertraline treatment of severe premenstrual syndromes. Freeman, Aug 579–584
Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. Steiner, Suppl 12, 17–21
Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. Pearlstein, Feb 101–109
Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. Ling, Suppl 12, 9–16

Primary Care

Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. Ling, Suppl 12, 9–16

Proteomics

New drug discovery in the postgenomic era: from genomics to proteomics [BRAINSTORMS]. Stahl, Dec 894–895

Psychobiology

Psychobiology of posttraumatic stress disorder. Nutt, Suppl 5, 24–29

Psychopharmacology

Seven habits of highly effective psychopharmacologists: overview [BRAINSTORMS]. Stahl, Apr 242–243
Seven habits of highly effective psychopharmacologists, part 2: begin with the end in mind [BRAINSTORMS]. Stahl, May 327–328
Seven habits of highly effective psychopharmacologists, part 3: sharpen the saw with selective choices of continuing medical education programs [BRAINSTORMS]. Stahl, June 401–402
Seven habits of highly effective psychopharmacologists, part 4: developing and implementing the vision [BRAINSTORMS]. Stahl, July 464–465

Psychosis

Antipsychotic treatment of psychosis and agitation in the elderly. Daniel, Suppl 14, 49–52
Emergency treatment of depression complicated by psychosis or agitation. Glick, Suppl 14, 43–48
Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Brook, Dec 933–941
Introduction: acute care of the agitated psychotic patient. Allen, Suppl 14, 3–4
Managing the agitated psychotic patient: a reappraisal of the evidence. Allen, Suppl 14, 11–20
Positive treatment effect of estradiol in postpartum psychosis: a pilot study. Ahokas, Mar 166–169
Rationale and guidelines for the inpatient treatment of acute psychosis. Feifel, Suppl 14, 27–32

Psychosocial Treatment

Posttraumatic stress disorder: psychological factors and psychosocial interventions. Hembree, Suppl 7, 33–39
Psychosocial treatment of posttraumatic stress disorder. Foa, Suppl 5, 43–48

Psychostimulants

Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. Kafka, Sept 664–670

Psychotherapy

Psychodynamic psychotherapy for PTSD [letters]. Plakun, Saporta; Foa reply, Oct 787–788

Psychotropic Drugs

Allergy to tartrazine in psychotropic drugs. Bhatia, July 473–476
Free drug fraction versus free drug concentration [letter]. Pies; DeVane reply, June 449

Quality of Life

Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients [CME]. Ritsner, Nov 880–889

Quetiapine

Clarification of anticholinergic effects of quetiapine [letter]. Goldstein, Sept 680
Clinical predictors of acute response with quetiapine in psychotic mood disorders. Zarate, Mar 185–189
Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. McConville, Apr 252–260
Possible case of quetiapine withdrawal syndrome [letter]. Thurstone, Aug 602–603
Review of quetiapine side effects. Garver, Suppl 8, 31–35

Race

Racial variation in antidepressant treatment in a Medicaid population. Melfi, Jan 16–21

Reboxetine

Clinical efficacy of reboxetine in major depression. Schatzberg, Suppl 10, 31–38
Reboxetine treatment of depression in Parkinson's disease [letter]. Lemke, Nov 872

Recovery

Recovery-oriented psychopharmacology: redefining the goals of antipsychotic treatment. Noordsy, Suppl 3, 22–29

Respiration

Restlessness of respiration as a manifestation of akathisia: five case reports of respiratory akathisia. Hirose, Oct 737–741

Risperidone

Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. Sharif, July 498–504
Effectiveness of risperidone in simple schizophrenia: a single case report [letter]. Hirose, Apr 300–301
Naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. Guille, Sept 638–642
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. Aubry, Sept 649–655
Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. Lane, Mar 209–214
Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer [letter]. Güzey, Aug 600–601
Risperidone side effects. Conley, Suppl 8, 20–25
Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. Feifel, Dec 909–911
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Kinon, Nov 833–840
Urinary incontinence with risperidone [letter]. Agarwal, Mar 219

St. John's Wort
Open-label trial of St. John's wort (*Hypericum perforatum*) in obsessive-compulsive disorder. Taylor, Aug 575–578
Schizoaffective Disorder
Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. Ciapparelli, May 329–334
Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. Sharif, July 498–504
Measuring patient symptom change on rural psychiatry units: utility of the Symptom Checklist-90 Revised. Ronan, July 493–497
Schizophrenia
Algorithm for the treatment of schizophrenia in the correctional setting: the Forensic Algorithm Project. Buscema, Oct 767–783
Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. Rosenheck, Sept 671–676
Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. Ciapparelli, May 329–334
Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. Sharif, July 498–504
Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients [CME]. Ritsner, Nov 880–889
Effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia [letter]. Martín, Dec 948
Effectiveness of risperidone in simple schizophrenia: a single case report [letter]. Hirose, Apr 300–301
Efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Keck, Suppl 3, 4–9
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. Melkersson, Oct 742–749
Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. Lu, Aug 594–599
Gender differences in severity of schizophrenia [letter]. King, Jan 61
Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum [CME]. Garver, Dec 964–972
Inappropriate masturbation and schizophrenia [letter]. Brooks JO, June 451
Melatonin improves sleep quality of patients with chronic schizophrenia. Shamir, May 373–377
Non-antidepressant treatment of premenstrual syndrome. Pearlstein, Suppl 12, 22–27
Novel antipsychotic use in schizophrenia [Academic Highlights]. Mar 223–232
Patients with schizophrenia at risk for excessive antipsychotic dosing. Walkup, May 344–348
Prevalence of spontaneous dyskinesia in schizophrenia. Fenton, Suppl 4, 10–14
Prodromal symptoms of relapse in a sample of Egyptian schizophrenic patients. Okasha, Oct 729–736
Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. Lane, Mar 209–214
Safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO study). Gómez, May 335–343
Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). Miyaoka, Nov 868–871
Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome): three case reports [letter]. Miyaoka, Apr 299–300
Sedative-Hypnotic Dependence
Treatment of sedative-hypnotic dependence: evaluating clinical predictors of outcome. Charney, Mar 190–195
Selective Serotonin Reuptake Inhibitors
Mirtazapine substitution in SSRI-induced sexual dysfunction. Gelenberg, May 356–360
Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. Fredman, June 403–408
Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. Kafka, Sept 664–670
SSRI-TCA combination in the treatment of resistant depression [letter]. Terao, July 529
Serotonin
Depression: the case for a monoamine deficiency. Delgado, Suppl 6, 7–11
Evidence for a biochemical lesion in depression. Leonard, Suppl 6, 12–17
History and evolution of the monoamine hypothesis of depression. Hirschfeld, Suppl 6, 4–6
Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. Steiner, Suppl 12, 17–21
Sertraline
Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. Kennedy, Apr 276–281
Double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. Newhouse, Aug 559–568
Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. Suri, Dec 942–946
Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Fava, Nov 863–867
Lack of sertraline efficacy probably due to an interaction with carbamazepine [letter]. Khan, July 526–527
Predictors of response to sertraline treatment of severe premenstrual syndromes. Freeman, Aug 579–584
Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. Pearlstein, Feb 101–109
Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Mehtonen, Feb 95–100
Sertraline treatment of panic disorder: response in patients at risk for poor outcome. Pollack, Dec 922–927
Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. Ravindran, Nov 821–827
Venlafaxine versus sertraline for major depressive disorder [letter]. Wise, Nov 873–874
Sexual Behavior
Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study. Coleman, Apr 282–284
Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. Kafka, Sept 664–670
Sexual Dysfunction
Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. Kennedy, Apr 276–281
Mirtazapine substitution in SSRI-induced sexual dysfunction. Gelenberg, May 356–360
Sexual dysfunction on fluvoxamine therapy [letter]. Laird; Nafziger reply, Jan 62–63
Sexual side effects of antidepressants. Rothschild, Suppl 11, 28–36
Side Effects see also specific side effects
Adverse events of fluoxetine: postmarketing compared with premarketing clinical trials [letter]. Musa, Nov 874
Adverse events related to olanzapine. Conley, Suppl 8, 26–30
Adverse neuropsychiatric reactions to herbal and over-the-counter "antidepressants." Pies, Nov 815–820
Antipsychotic drug side effect issues in bipolar manic patients. Zarate, Suppl 8, 52–63
Clinical issues in long-term treatment with antidepressants. Zajecka, Suppl 2, 20–25
Overview of side effects caused by typical antipsychotics. Arana, Suppl 8, 5–13
Review and management of clozapine side effects. Miller DD, Suppl 8, 14–19
Review of quetiapine side effects. Garver, Suppl 8, 31–35
Risperidone side effects. Conley, Suppl 8, 20–25
Side effects of antipsychotics in the elderly. Masand, Suppl 8, 43–51
Sleep
Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. Nofzinger, Nov 858–862
Melatonin improves sleep quality of patients with chronic schizophrenia. Shamir, May 373–377
Treatment issues related to sleep and depression. Thase, Suppl 11, 46–50
Social Functioning
Social functioning and the treatment of depression. Weissman MM, Suppl 1, 33–38
Social functioning in depression: a review. Hirschfeld, Apr 268–275
Substance Use Disorders
Divalproex sodium for alcohol withdrawal and relapse prevention: a case report [letter]. Longo, Dec 947–948

Divalproex sodium in substance abusers with mood disorder. Albanese, Dec 916–921
Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. Weiss, May 361–367
Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. Schubiner, Apr 244–251
Psychiatric care of patients with depression and comorbid substance use disorders. Montoya, Sept 698–705

Suicide
Effects of light therapy on suicidal ideation in patients with winter depression. Lam, Jan 30–32
Efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Keck, Suppl 3, 4–9
Lithium in unipolar depression and the prevention of suicide. Coppen, Suppl 9, 52–56
Memory impairment in those who attempted suicide by benzodiazepine overdose [CME]. Verwey, June 456–459
Reduced suicide risk during lithium maintenance treatment. Tondo, Suppl 9, 97–104
Suicide and bipolar disorder. Jamison, Suppl 9, 47–51

Sulindac
Increased lithium concentrations reported in patients treated with sulindac [letter]. Jones, July 527–528

Symptom Checklist-90 Revised
Measuring patient symptom change on rural psychiatry units: utility of the Symptom Checklist-90 Revised. Ronan, July 493–497

Syndrome of Inappropriate Secretion of Antidiuretic Hormone
SIADH with multiple antidepressants in a geriatric patient [letter]. Blass, June 448–449

Tardive Dyskinesia see Dyskinesia

Tartrazine
Allergy to tartrazine in psychotropic drugs. Bhatia, July 473–476

Texas Medication Algorithm Project
Texas Medication Algorithm Project patient and family education program: a consumer-guided initiative. Toprac, July 477–486

Topiramate
Treatment of binge-eating disorder with topiramate: a clinical case series. Shapira, May 368–372

Tourette's Disorder
Relationship between types and severity of repetitive behaviors in Gilles de la Tourette's disorder and obsessive-compulsive disorder. Cath, July 505–513
Sensory phenomena in obsessive-compulsive disorder and Tourette's disorder. Miguel, Feb 150–156

Tranylcypromine
Bupropion-tranylcypromine combination for treatment-refractory depression [letter]. Pierre, June 450–451

Trichotillomania
Placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Ninan, Jan 47–50

Tricyclic Antidepressants
SSRI-TCA combination in the treatment of resistant depression [letter]. Terao, July 529

Urinary Incontinence
Olanzapine-induced urinary incontinence: treatment with ephedrine [letter]. Vernon, Aug 601–602
Urinary incontinence with risperidone [letter]. Agarwal, Mar 219

Valproate
Appropriate clinical management of women taking valproate. Piontek, Mar 161–163
Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment. Juckel, Aug 585–593
Divalproex sodium for alcohol withdrawal and relapse prevention: a case report [letter]. Longo, Dec 947–948
Divalproex sodium in substance abusers with mood disorder. Albanese, Dec 916–921
Gastrointestinal adverse effects with divalproex sodium and valproic acid [letter]. Wagner; Zarate reply, Apr 302–303
Low-dose lithium augmentation of divalproex in geriatric mania [letter]. Goldberg, Apr 304
Serum valproate levels in 6 breastfeeding mother-infant pairs. Piontek, Mar 170–172
Side effect profile of enteric-coated divalproex sodium versus valproic acid [letter]. Levine, Sept 680–681
Use of sodium valproate in violent and aggressive behaviors: a critical review. Lindenmayer, Feb 123–128

Valproic Acid see Valproate

Venlafaxine
Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. Kennedy, Apr 276–281
Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings. Gómez Gómez, Apr 285–289
Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Mehtonen, Feb 95–100
Venlafaxine and vivid dreaming [letter]. Zullino, Aug 600
Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Zanardi, Jan 26–29
Venlafaxine versus sertraline for major depressive disorder [letter]. Wise, Nov 873–874

Violence
Use of sodium valproate in violent and aggressive behaviors: a critical review. Lindenmayer, Feb 123–128

War
Posttraumatic residues of captivity: a follow-up of Israeli ex-prisoners of war. Neria, Jan 39–46

Weight
Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Fava, Nov 863–867
Is antipsychotic drug-induced weight gain associated with a favorable clinical response? [letter]. Lamberti; Ganguli reply, Sept 678
Prevalence of overweight and obesity in bipolar patients. Elmslie, Mar 179–184
Weight gain and antidepressants. Fava, Suppl 11, 37–41
Weight gain and antipsychotic medication. Blackburn, Suppl 8, 36–41

Women
Appropriate clinical management of women taking valproate. Piontek, Mar 161–163
Enhancing pharmacologic effects in the treatment of depression in women. Kornstein, Suppl 11, 18–27
Hormonal side effects in women: typical versus atypical antipsychotic treatment. Dickson, Suppl 3, 10–15
Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. Frank, Jan 51–57
Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. Rasgon, Mar 173–178
Mood stabilizers during breastfeeding: a review. Chaudron, Feb 79–90
Paroxetine levels in postpartum depressed women, breast milk, and infant serum. Misri, Nov 828–832
Positive treatment effect of estradiol in postpartum psychosis: a pilot study. Ahokas, Mar 166–169
Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. Pearlstein, Feb 101–109
Serum valproate levels in 6 breastfeeding mother-infant pairs. Piontek, Mar 170–172

Ziprasidone
Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Brook, Dec 933–941

Zolpidem
Zolpidem-related delirium: a case report [letter]. Freudenreich, June 449–450

Journal of Clinical Psychiatry

Author Index to Volume 61: January 2000 Through December 2000

Aamo T see Güzey C
Abbasi QA see Buscema CA
Agarwal V. Urinary incontinence with risperidone [letter]. Mar 219
Ahn YM see Kang UG
Ahokas A, Aito M, Rimon R. Positive treatment effect of estradiol in postpartum psychosis: a pilot study. Mar 166–169
Aito M see Ahokas A
Alahi P see Thurstone CC
Alarcón RD. Review of Nicholi AM Jr (ed): *The Harvard Guide to Psychiatry, 3rd ed.* Sept 684–685
Albanese MJ, Clodfelter RC Jr, Khantzian EJ. Divalproex sodium in substance abusers with mood disorder. Dec 916–921
Alborzian S see Brody AL
Alda M see Duffy A
Allen MH. Introduction. Acute care of the agitated psychotic patient. Suppl 14, 3–4
Allen MH. Managing the agitated psychotic patient: a reappraisal of the evidence. Suppl 14, 11–20
Altshuler LL see Hendrick V; Rasgon NL; Suri RA
Amsterdam JD see McGrath PJ
Anand A, Charney DS. Norepinephrine dysfunction in depression. Suppl 10, 16–24
Anis Y see Shamir E
Antonacci DJ, de Groot CM. Clozapine treatment in a population of adults with mental retardation. Jan 22–25
Arana GW. Overview of side effects caused by typical antipsychotics. Suppl 8, 5–13
Arvanitis LA see McConville BJ
Ascher JA see Calabrese JR; Weihs KL
Ashton AK. Lack of desipramine toxicity with citalopram [letter]. Feb 144
Astin MC see Rothbaum BO
Aubry JM, Simon AE, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. Sept 649–655
Augenstein EJ. Review of Miller LJ (ed): *Postpartum Mood Disorders.* May 391
Baab S see Piontek CM
Bacchiochi JR see Kennedy SH
Baer L see Miguel EC
Bagby RM see Kennedy SH
Baldessarini RJ see Tondo L
Baldwin D see Hirschfeld RMA
Baleriaux M see Kornreich C
Ballenger JC. Introduction: focus on posttraumatic stress disorder. Suppl 5, 3
Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, McFarlane AC, Shalev AY. Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. Suppl 5, 60–66
Barak P see Ritsner M
Barak Y see Shamir E
Barnhill LJ see Horrigan JP
Barry DJ see Buscema CA
Basson BR see Kinon BJ
Batey SR see Weihs KL
Batzar ED see Newhouse PA; Pearlstein TB
Baxter LR Jr see Brody AL
Beasley CM Jr, Nilsson ME, Koke SC, Gonzales JS. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. Oct 722–728
Beasley CM Jr see McGrath PJ
Behnke K see Mehtonen O
Benabarre A see Colom F
Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. Sept 656–663
Bennett BK see Hickie IB
Berber MJ. WATCHERS: recognizing generalized anxiety disorder [letter]. June 447
Berman SR see Nofzinger EA; Thase ME
Bernet W. Review of American Psychiatric Association: *Dangerous Sex Offenders: A Task Force Report of the American Psychiatric Association.* Sept 683
Bernet W. Review of Brown D, Scheflin AW, Hammond DC: *Memory, Trauma Treatment, and the Law.* Aug 605
Bertino JS Jr see Nafziger AN
Bertschy G see Aubry JM
Bhatia MS. Allergy to tartrazine in psychotropic drugs. July 473–476
Bickman L. Review of Speer DC: *Mental Health Outcome Evaluation.* Aug 607–608
Bishry Z see Okasha A
Blackburn GL. Weight gain and antipsychotic medication. Suppl 8, 36–41
Blass DM, Pearson VE. SIADH with multiple antidepressants in a geriatric patient [letter]. June 448–449
Blumer D, Wakhlu S, Montouris G, Wyler A. Treatment of the interictal psychoses. Feb 110–122
Boiman EE see Ghaemi SN
Borba CP, Henderson DC. Citalopram and clozapine: potential drug interaction [letter]. Apr 301–302
Bourgeois ML see Hirschfeld RM
Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. Suppl 9, 35–40
Bowden CL see Calabrese JR
Boyer C see Walkup JT
Brady KT. Difficulties in diagnosis and management of bipolar disorder: three case presentations. Suppl 13, 32–37
Brady KT, Killeen TK, Brewerton T, Lucerini S. Comorbidity of psychiatric disorders and posttraumatic stress disorder. Suppl 7, 22–32
Brecher M see Goldstein JM
Breier A see Gómez JC
Brewerton T see Brady KT
Brismar KE see Melkersson KI
Brody AL, Saxena S, Fairbanks LA, Alborzian S, Demaree HA, Maidment KM, Baxter LR Jr. Personality changes in adult subjects with major depressive disorder or obsessive-compulsive disorder treated with paroxetine. May 349–355
Brook S, Lucey JV, Gunn KP, for the Ziprasidone I.M. Study Group. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Dec 933–941
Brooks BA. Review of Wilens TE: *Straight Talk About Psychiatric Medications for Kids.* Jan 65
Brooks JO III, Waikar MV. Inappropriate masturbation and schizophrenia [letter]. June 451
Brotman MA, Fergus EL, Post RM, Leverich GS. High exposure to neuroleptics in bipolar patients: a retrospective review [CME]. Jan 68–72
Brown CS see Pearlstein TB
Brown KL see McConville BJ
Brunette M see Noordsy DL
Buffa C see Dallocchio C
Burt VK see Rasgon NL
Buscema CA, Abbasi QA, Barry DJ, Lauve TH. Algorithm for the treatment of schizophrenia in the correctional setting: the Forensic Algorithm Project. Oct 767–783
Buysse DJ see Frank E
Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET, for the Lamictal 614 Study Group. Double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Nov 841–850
Calcagno JL see Suri RA

Carbonell EF see Gómez JC
Carrasco PR see Gómez JC
Casey DE. Introduction. Antipsychotic standard of care: redefining the definition of atypical antipsychotics. Suppl 3, 3
Casey DE. Introduction: update on tardive dyskinesia. Suppl 4, 3–4
Casey DE. Tardive dyskinesia: pathophysiology and animal models. Suppl 4, 5–9
Cassano GB see Ciapparelli A; Ravindran AV
Castellanos A see Menza MA
Cath DC, Spinhoven P, van de Wetering BJM, Hoogduin CAH, Landman AD, van Woerkom TCAM, Roos RAC, Rooijmans HGM. Relationship between types and severity of repetitive behaviors in Gilles de la Tourette's disorder and obsessive-compulsive disorder. July 505–513
Catron DJ. Review of Gatchel RJ, Turk DC: *Psychosocial Factors in Pain: Clinical Perspectives.* April 305
Cazzaro M see Fava GA
Chaney RO see McConville BJ
Chang S see Rosenheck R
Chang W-H see Lane H-Y; Lu M-L
Charney DA, Paraherakis AM, Gill KJ. Treatment of sedative-hypnotic dependence: evaluating clinical predictors of outcome. Mar 190–195
Charney DS see Anand A; Rosenheck R
Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review. Feb 79–90
Chelminski I, Zimmerman M, Mattia JI. Diagnosing melancholia [letter]. Nov 874–875
Chen G see Manji HK
Chen K-P see Lu M-L
Chen YR see Varner RV
Chengappa KNR see Levine J; Sylvester AP
Chentsova-Dutton YE see Zisook S
Cherry CR see Frank E
Chesen CL see Gelenberg AJ
Chiavacci MC see Ciapparelli A
Chiu W-C see Lane H-Y
Choe Y see Rosenheck R
Chou JC-Y see Lane H-Y
Christensen JD see Garver DL
Chung DW-S see Leung C
Chung SJ see Kang UG
Ciapparelli A, Dell'Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. May 329–334
Clary CM see Newhouse PA; Pollack MH
Claxton A, de Klerk E, Parry M, Robinson JM, Schmidt ME. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. Dec 928–932
Clodfelter RC Jr see Albanese MJ
Clouse J see Sullivan EM
Coffey BJ see Miguel EC
Cohen LS. Introduction: new trends in treating premenstrual dysphoric disorder. Suppl 12, 3–4
Cohen LS see Soares CN
Coleman E, Gratzer T, Nesvacil L, Raymond NC. Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study. Apr 282–284
Colom F, Vieta E, Martínez-Arán A, Reinares M, Benabarre A, Gastó C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. Aug 549–555
Compton MT, Nemeroff CB. Treatment of bipolar depression. Suppl 9, 57–67
Conley RR. Risperidone side effects. Suppl 8, 20–25
Conley RR, Meltzer HY. Adverse events related to olanzapine. Suppl 8, 26–30
Conner TM see Toprac MG
Copeland ME see Noordsy DL
Coppen A. Lithium in unipolar depression and the prevention of suicide. Suppl 9, 52–56
Corenblum B see Dickson RA
Craighead WE, Miklowitz DJ. Psychosocial interventions for bipolar disorder. Suppl 13, 58–64
Cramer J see Rosenheck R
Crippa JAS see Hallak JEC
Crismon ML see Toprac MG
Croghan TW see Melfi CA
Crowder MK. Review of Hales RE, Yudofsky SC: *Essentials of Clinical Psychiatry Based on The American Psychiatric Press Textbook of Psychiatry, 3rd ed.* Nov 877
Crowder MK. Review of Hilty DM, Hales RE, Yudofsky SC. *Study Guide to Essentials of Clinical Psychiatry.* Nov 877
Currier GW. Atypical antipsychotic medications in the psychiatric emergency service. Suppl 14, 21–26
Cyrus PA see Raskind MA
Dallocchio C, Buffa C, Mazzarello P. Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease [letter]. Jan 64
Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. Suppl 14, 49–52
da Silva Prado H see Miguel EC
Davidson JRT. Introduction: new strategies for the treatment of posttraumatic stress disorder. Suppl 7, 3–4
Davidson JRT. Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. Suppl 5, 52–56
Davidson JRT see Ballenger JC; Foa EB; Hidalgo RB
Dees M see Toprac MG
de Groot CM see Antonacci DJ
Dekel R see Solomon Z
de Klerk E see Claxton A
Delgado PL. Approaches to the enhancement of patient adherence to antidepressant medication treatment. Suppl 2, 6–9
Delgado PL. Depression: the case for a monoamine deficiency. Suppl 6, 7–11
Delgado PL, Moreno FA. Role of norepinephrine in depression. Suppl 1, 5–12
Delgado PL see Gelenberg AJ
Dell'Osso L see Ciapparelli A
Delrahim S see Hendrick V
Demaree HA see Brody AL
DeMartinis N, Rynn M, Rickels K, Mandos L. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. Feb 91–94
Denicoff KD see Frye MA
Dennehy EB see Suppes TP
DeVane CL. Pharmacologic characteristics of ideal antidepressants in the 21st century. Suppl 11, 4–8
DeVane CL, Pollock BG. Reply to Pies R: Free drug fraction versus free drug concentration [letter]. June 449
Dickens SE see Kennedy SH
Dickson RA, Seeman MV, Corenblum B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. Suppl 3, 10–15
Dilts SL. Review of Galanter M, Kleber HD (eds): *The American Psychiatric Press Textbook of Substance Abuse Treatment, 2nd ed.* Nov 878
Dobie DJ see Raskind MA
Dollard KM see Ronan GF
Donahue RMJ see Weihs KL
Doraiswamy PM see Newhouse PA
do Rosário-Campos MC see Miguel EC
do Valle R see Miguel EC
Dreer LE see Ronan GF
Dresel S see Juckel G
Druss BG, Hoff RA, Rosenheck RA. Underuse of antidepressants in major depression: prevalence and correlates in a national sample of young adults [CME]. Mar 234–237
Duffy A, Grof P, Robertson C, Alda M. Implications of genetic studies of major mood disorders for clinical practice. Sept 630–637
Dunayevich E, Sax KW, Keck PE Jr, McElroy SL, Sorter MT, McConville BJ, Strakowski SM. Twelve-month outcome in bipolar patients with and without personality disorders. Feb 134–139; Correction, July 529
Dunner DL. Introduction: new strategies for improving the treatment of depression. Suppl 11, 3
Dunner DL. Optimizing lithium treatment. Suppl 9, 76–81
Dunner DL. Review of Halbreich U, Montgomery SA (eds): *Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders.* Sept 682
Earl NL see Calabrese JR
Early JJ see Teter CJ
Eccard MB see Ninan PT
Ehrentraut S see Rothenhäusler H
Eisfeld BS see Kennedy SH
Elam LC. Review of Spurlock J (ed): *Black Psychiatrists and American Psychiatry.* Jan 66
El Dawla AS see Okasha A
El Fiki MR see Okasha A
Eling P see Verwey B
Elizur A see Shamir E
Ellenor GL see Zisook S
Elliott MA see Koran LM
Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. Mar 179–184
El Rasheed AH see Okasha A
Endicott J. History, evolution, and diagnosis of premenstrual dysphoric disorder. Suppl 12, 5–8
Endicott J see Pearlstein TB; Ritsner M
Enoch D see Solomon Z

Evans DL. Bipolar disorder: diagnostic challenges and treatment considerations. Suppl 13, 26–31
Fabbri S see Fava GA
Fairbanks LA see Brody AL
Fasiczka AL see Nofzinger EA; Thase ME
Fava GA, Grandi S, Rafanelli C, Fabbri S, Cazzaro M. Explanatory therapy in hypochondriasis [CME]. Apr 317–322
Fava M. Introduction: optimizing treatment outcome in depression. Suppl 2, 4–5
Fava M. Management of nonresponse and intolerance: switching strategies. Suppl 2, 10–12
Fava M. New approaches to the treatment of refractory depression. Suppl 1, 26–32
Fava M. Weight gain and antidepressants. Suppl 11, 37–41
Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. Nov 863–867
Fava M see Fredman SJ; Schmidt ME
Fawcett J see McGrath PJ
Feifel D. Rationale and guidelines for the inpatient treatment of acute psychosis. Suppl 14, 27–32
Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. Dec 909–911
Feinberg SS. Clarifying the safety of the MAOI diet and pizza [letter]. Feb 145
Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. Suppl 4, 10–14
Fenzi M see Ciapparelli A
Fergus EL see Brotman MA
Figley CR, Leeds AM, Tinker-Wilson SA, van der Kolk BA. Further discussion of EMDR for treatment of PTSD [letter with reply]. Oct 785–786
Findling RL. Review of Perry PJ, Alexander B, Liskow BI: *Psychotropic Drug Handbook, 7th ed.* Mar 222
Fishel-Ingram P. Review of Hargreaves WA, Shumway M, Hu T, Cuffel B: *Cost-Outcome Methods for Mental Health.* Apr 305–306
Fletcher KE see Zarate CA Jr
Foa EB. Psychosocial treatment of posttraumatic stress disorder. Suppl 5, 43–48
Foa EB, Davidson JRT, Frances A. Reply to Figley CR: Further discussion of EMDR for treatment of PTSD [letter]. Oct 786
Foa EB, Davidson JRT, Frances A. Reply to Peterson G: EMDR for treatment of PTSD [letter]. Oct 784–785
Foa EB see Ballenger JC; Hembree EA
Fontaine CS see Weiner MF
Fossion P see Kornreich C
Foster BM see Weiner MF
Foster KD see McConville BJ
Frachtling RJ see Teter CJ
Frances A see Foa EB
Franchini L see Zanardi R
Franco S. Review of Hays S: *The Cultural Contradictions of Motherhood.* July 530–531
Frank E, Grochcoinski VJ, Spanier CA, Buysse DJ, Cherry CR, Houck PR, Stapf DM, Kupfer DJ. Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. Jan 51–57
Frank E see Pearlstein TB; Thase ME
Frank RG see Sullivan EM
Frazer A. Norepinephrine involvement in antidepressant action. Suppl 10, 25–30
Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. June 403–408
Freeman EW, Sondheimer SJ, Polansky M, Garcia-Espagna B. Predictors of response to sertraline treatment of severe premenstrual syndromes. Aug 579–584
Freeman EW see Pearlstein TB; Rickels K
Freudenreich O, Goff DC. Colon perforation and peritonitis associated with clozapine [letter]. Dec 950–951
Freudenreich O, Menza M. Zolpidem-related delirium: a case report [letter]. June 449–450
Friedman ES see Thase ME
Friedman LM see McConville BJ
Friedman MJ. What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy? Suppl 7, 44–51
Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM. Increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. Jan 9–15
Frye MA see Suri RA
Fuchs DC. Review of Lewis JM III, Blotcky MJ: *Child Therapy Concepts, Strategies, and Decision Making.* Aug 605–606
Fuller MA see Vernon LT
Gabbard GO. Review of Millon T, Davis R: *Personality Disorders in Modern Life.* Feb 148
Gallinat J see Juckel G
Ganguli R. Reply to Lamberti JS: Is antipsychotic drug-induced weight gain associated with a favorable clinical response? [letter]. Sept 678
Garber J. Review of Cassidy J, Shaver PR (eds): *Handbook of Attachment: Theory, Research, and Clinical Applications.* Oct 790
Garcia-Espagna B see Freeman EW
Garver DL. Review of McGorry PD, Jackson HJ (eds): *The Recognition and Management of Early Psychosis: A Preventive Approach.* June 453
Garver DL. Review of quetiapine side effects. Suppl 8, 31–35
Garver DL, Holcomb JA, Christensen JD. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum [CME]. Dec 964–972
Gastó C see Colom F
Gelenberg AJ. In memoriam: Seymour S. Kety, M.D. July 525
Gelenberg AJ. Special thanks [letter]. April 299
Gelenberg AJ, Chesen CL. How fast are antidepressants? Oct 712–721
Gelenberg AJ, McGahuey C, Laukes C, Okayli G, Moreno F, Zentner L, Delgado P. Mirtazapine substitution in SSRI-induced sexual dysfunction. May 356–360; Correction, Sept 681
Gershon S see Soares JC
Ghaemi SN. New treatments for bipolar disorder: the role of atypical neuroleptic agents. Suppl 14, 33–42
Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study [CME]. Oct 804–808
Ghaemi SN see Glick RL; Guille C
Gibbons EW see Suppes T
Giedd JN. Bipolar disorder and attention-deficit/hyperactivity disorder in children and adolescents. Suppl 9, 31–34
Giedke H see Sieche A
Gill KJ see Charney DA
Gillin JC see Zisook S
Gilmore JA see Kinon BJ
Ginzburg K see Solomon Z
Gitlin MJ see Hendrick V; Pierre JM; Suri RA
Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. Suppl 4, 21–26
Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. Suppl 3, 16–21
Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. Suppl 4, 15–20
Glick RL, Ghaemi SN. Emergency treatment of depression complicated by psychosis or agitation. Suppl 14, 43–48
Goff DC see Freudenreich O
Goldberg JF. Treatment guidelines: current and future management of bipolar disorder. Suppl 13, 12–18
Goldberg JF, Sacks MH, Kocsis JH. Low-dose lithium augmentation of divalproex in geriatric mania [letter]. Apr 304
Goldin V see Ritsner M
Goldman HH see Sullivan EM
Goldsmith TD see Shapira NA
Goldstein JM, Brecher M. Clarification of anticholinergic effects of quetiapine [letter]. Sept 680
Gómez JC, Sacristán JA, Hernández J, Breier A, Carrasco PR, Saiz CA, Carbonell EF, Group ES. Safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO study). May 335–343
Gómez Gómez JM[a], Perramón CT. Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings. Apr 285–289
Gonzales JS see Beasley CM Jr
Goodwin FK see Ghaemi SN
Gorman JM. Introduction: spectrum of depression: new treatment approaches. Suppl 1, 3–4
Gorman JM, Sullivan G. Noradrenergic approaches to antidepressant therapy. Suppl 1, 13–16
Goss-Bley AI see Nafziger AN
Grandi S see Fava GA
Gratzer T see Coleman E
Greene PL see Calabrese JR
Greenfield SF see Weiss RD
Greil W see Juckel G
Griffin ML see Weiss RD
Griffiths RI see Sullivan EM

Grochcoinski VJ see Frank E
Grof P see Duffy A
Grohmann R see Stübner S
Group ES see Gómez JC
Gudeman D see Rasgon NL
Guelfi JD see Ravindran AV
Guille C, Sachs GS, Ghaemi SN. Naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. Sept 638–642
Gumnick JF, Nemeroff CB. Problems with currently available antidepressants. Suppl 10, 5–15
Gunn KP see Brook S
Güzey C, Aamo T, Spigset O. Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer [letter]. Aug 600–601
Ha JH see Kang UG
Hahn C-G see Lenox RH
Halbreich U see Pearlstein TB
Hallak JEC, Crippa JAS, Zuardi AW. Treatment of koro with citalopram [letter]. Dec 951
Hammen C see Hendrick V
Hammond CM see Wagner PG
Hampel H see Stübner S
Hanna MP see Melfi CA
Hansell S see Walkup JT
Harrison WM see Pearlstein TB
Haskett RF see Pearlstein TB; Sylvester AP
Hattab H see Vernon LT
Healy D. Case for an individual approach to the treatment of depression. Suppl 6, 18–23
Healy D see Hirschfeld RMA
Hegerl U see Juckel G
Hembree EA, Foa EB. Posttraumatic stress disorder: psychological factors and psychosocial interventions. Suppl 7, 33–39
Henderson DC see Borba CP
Henderson W see Rosenheck R
Hendrick V, Altshuler LL, Gitlin MJ, Delrahim S, Hammen C. Gender and bipolar illness [CME]. May 393–396
Hendrick V see Rasgon NL
Hennen JA see Kafka MP; Weiss RD
Herbert RJ see Sullivan EM
Hernández J see Gómez JC
Heubi JE see McConville BJ
Hickie IB, Wilson AJ, Wright JM, Bennett BK, Wakefield D, Lloyd AR. Randomized, double-blind, placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. Sept 643–648
Hidalgo RB, Davidson JRT. Posttraumatic stress disorder: epidemiology and health-related considerations. Suppl 7, 5–13
Higuchi H see Takahashi H
Hilligoss NM see Littrell KH
Hippius H see Stübner S
Hirose S. Effectiveness of risperidone in simple schizophrenia: a single case report [letter]. Apr 300–301
Hirose S. Restlessness of respiration as a manifestation of akathisia: five case reports of respiratory akathisia. Oct 737–741
Hirschfeld RMA. History and evolution of the monoamine hypothesis of depression. Suppl 6, 4–6
Hirschfeld RMA, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Möller H-J, Healy D, Baldwin D, Humble M, Versiani M, Montenegro R, Bourgeois ML. Social functioning in depression: a review. Apr 268–275
Hoff RA see Druss BG
Hoffman G see Kornreich C
Holcomb JA see Garver DL
Hollweg M see Stübner S
Honigfeld G. Clozapine versus chlorpromazine in geriatric patients [letter]. Jan 63–64
Hoog SL see Fava M
Hoogduin CAH see Cath DC
Hopkins C see Toprac MG
Horiguchi J see Miyaoka T
Horrigan JP, Barnhill LJ. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. June 414–417
Hoshino R see Iwata Y
Houck PR see Frank E
Houser TL see Weihs KL
Hubbard JR. Review of Finley JR, Lenz BS: *The Chemical Dependence Treatment Documentation Sourcebook.* June 452–453
Huggins T see Frye MA
Hulting A-L see Melkersson KI
Humble M see Hirschfeld RMA
Hummel LM. Review of Koenig HG (ed): *Handbook of Religion and Mental Health.* Oct 789
Hwang S see Suri RA
Iijima M see Miyaoka T
Ikemura N see Terao T
Inagaki T see Miyaoka T
Itoga M see Miyaoka T
Iwata Y, Kotani Y, Hoshino R, Takei N, Iyo M, Mori N. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder [letter]. July 528–529
Iyo M see Iwata Y
Jamison KR. Suicide and bipolar disorder. Suppl 9, 47–51
Jann MW see Lu M-L
Jefferson JW see Chaudron LH
Jenike MA see Miguel EC
Jeste DV. Tardive dyskinesia in older patients. Suppl 4, 27–32
Johnson BA. Review of Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds): *Substance Abuse: A Comprehensive Textbook, 3rd ed.* July 530
Johnson CG see Littrell KH
Jones MT, Stoner SC. Increased lithium concentrations reported in patients treated with sulindac [letter]. July 527–528
Jongh AD see Greenwald R
Joseph DI. Review of Shea SC: *The Practical Art of Suicide Assessment: A Guide for Mental Health Professionals and Substance Abuse Counselors.* Sept 683–684
Juckel G, Hegerl U, Mavrogiorgou P, Gallinat J, Mager T, Tigges P, Dresel S, Schröter A, Stotz G, Meller I, Greil W, Möller H-J. Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment. Aug 585–593
Judge R see Fava M; Schmidt ME
Jurgis G see Rosenheck R
Kafka MP, Hennen J. Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. Sept 664–670
Kam IWK see Leung C
Kang UG, Kwon JS, Ahn YM, Chung SJ, Ha JH, Koo YJ, Kim YS. Electrocardiographic abnormalities in patients treated with clozapine. June 441–446
Kanter ED see Raskind MA
Kapfhammer H-P see Rothenhäusler H-B
Kaplan M. Atypical antipsychotics for treatment of mixed depression and anxiety [letter]. May 388–389
Kapur S see Remington GJ
Kashuba AD see Nafziger AN
Kasper S see Hirschfeld RMA
Katerndahl DA. Predictors of the development of phobic avoidance [CME]. Aug 618–623
Katerndahl DA, Talamantes M. Comparison of persons with early- versus late-onset panic attacks. June 422–427
Kaufman K see Menza MA
Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Suppl 4, 33–38
Keck PE Jr, Strakowski SM, McElroy SL. Efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Suppl 3, 4–9
Keck PE Jr see Dunayevich E
Keller MB. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. Dec 896–908
Keller MB see Hirschfeld RMA
Kelly B see Schubiner H
Kennedy SH, Bagby RM, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. Apr 276–281
Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. Suppl 5, 4–12
Kessler RC see Ballenger JC
Ketter TA see Frye MA
Khan A, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine [letter]. July 526–527
Khantzian EJ see Albanese MJ
Kienke AS see Fredman SJ
Kilger E see Rothenhäusler H-B
Killeen TK see Brady KT
Kilts CD. In vivo imaging of the pharmacodynamics and pharmacokinetics of lithium. Suppl 9, 41–46
Kim J see Misri S
Kim YS see Kang UG
Kin NMK see Steiger H
King PD. Gender differences in severity of schizophrenia [letter]. Jan 61
Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL. Strategies for switching from

conventional antipsychotic drugs or risperidone to olanzapine. Nov 833–840
Kline NA see Zisook S
Knight BT see Ninan PT
Kobak KA see Taylor H
Kocsis JH. New strategies for treating chronic depression. Suppl 11, 42–45
Kocsis JH see Goldberg JF
Kodsi AB see Zisook S
Kohnen R see Benkert O
Koke SC see Beasley CM Jr; Fava M
Koo YJ see Kang UG
Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. July 514–517
Korenman S see Rasgon NL
Kornreich C, Fossion P, Hoffman G, Baleriaux M, Pelc I. Treatment of Kleine-Levin syndrome: melatonin on the starting block [letter]. Mar 215
Kornstein SG, McEnany G. Enhancing pharmacologic effects in the treatment of depression in women. Suppl 11, 18–27
Kostaras X see Misri S
Kotani Y see Iwata Y
Kotsaftis A see Lindenmayer J
Krishnan KRR see Newhouse PA
Kronfol Z. Review of Chaleby KS, Racy J (eds): *Psychotherapy With the Arab Patient.* May 390–391
Kruger M see Schubiner H
Kupfer DJ see Frank E
Kuroda S see Wada K
Kusumakar V see Calabrese JR
Kwon JS see Kang UG
Labay LE see Walkup JT
Ladouceur C see Steiger H
Laird LK. Sexual dysfunction on fluvoxamine therapy [letter]. Jan 62
Lam RW, Tam EM, Shiah I-S, Yatham LN, Zis AP. Effects of light therapy on suicidal ideation in patients with winter depression. Jan 30–32
Lamberti JS. Is antipsychotic drug-induced weight gain associated with a favorable clinical response? [letter] Sept 678
Lamictal 614 Study Group see Calabrese JR
Landman AD see Cath DC
Lane H-Y, Chiu W-C, Chou JC-Y, Wu S-T, Su M-H, Chang W-H. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. Mar 209–214
Lane H-Y see Lu M-L
Lane RM see Ravindran AV
Lantz C see Frye MA
Laudon M see Shamir E
Laukes C see Gelenberg AJ
Lauve TH see Buscema CA
Leckman JF see Miguel EC
Lecrubier Y see Ballenger JC
Lee C see Smyth NJ
Lee Y see Wada K
Leeds AM see Figley CR
Lemke MR. Reboxetine treatment of depression in Parkinson's disease [letter]. Nov 872
Lenox RH, Hahn C-G. Overview of the mechanism of action of lithium in the brain: fifty-year update. Suppl 9, 5–15
Lenox RH see Manji HK
Leonard BE. Evidence for a biochemical lesion in depression. Suppl 6, 12–17
Leonard S see Steiger H
Lerner V, Matar MA, Polyakova I. Nefazodone-associated subjective complaints of burning sensations [letter]. Mar 216–217
Leung C, Chung DWS, Kam IWK, Wat KHY. Multiple rib fractures secondary to severe tardive dystonia and respiratory dyskinesia [letter]. Mar 215–216
Leverich GS see Brotman MA; Frye MA
Levi LD. Review of Jacobs SC: *Traumatic Grief: Diagnosis, Treatment, and Prevention.* July 531–532
Levin H, Reddy R. Clozapine in the treatment of neuroleptic-induced blepharospasm: a report of 4 cases. Feb 140–143
Levine J, Chengappa KNR, Parepally H. Side effect profile of enteric-coated divalproex sodium versus valproic acid [letter]. Sept 680–681
Liberman RP see Tsuang J
Liddle PF see Stip E
Lin K-M, Wonodi I. Review of Okpaku SO (ed): *Clinical Methods in Transcultural Psychiatry.* Mar 220–221
Lindenmayer J-P. Pathophysiology of agitation. Suppl 14, 5–10
Lindenmayer J-P, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. Feb 123–128
Ling FW. Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. Suppl 12, 9–16
Littrell KH, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH. Switching clozapine responders to olanzapine. Dec 912–915
Littrell SH see Littrell KH
Lloyd AR see Hickie IB
Lockhart N see Schubiner H
Lomax JW II. Review of Millon T: *Personality-Guided Therapy.* June 453–454
Longo LP. Divalproex sodium for alcohol withdrawal and relapse prevention: a case report [letter]. Dec 947–948
Lu M-L, Lane H-Y, Chen K-P, Jann MW, Su M-H, Chang W-H. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. Aug 594–599
Lucerini S see Brady KT
Lucey JV see Brook S
Lyketsos CG. Review of Robinson RG: *The Clinical Neuropsychiatry of Stroke.* Feb 147
Madrid A see Zarate CA Jr
Maeda T see Miyaoka T
Mager T see Juckel G
Maidment K see Brody AL
Malcolm S see Kinon BJ
Mandos L see Demartinis N
Manji HK, Lenox RH. Nature of bipolar disorder. Suppl 13, 42–57
Manji HK, Moore GJ, Chen G. Lithium up-regulates the cytoprotective protein bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. Suppl 9, 82–96
Mann JI see Elmslie JL
Marcus SC see Montoya ID
Mardekian J see Pollack MH
Marsteller FA see Ninan PT
Martín JC, Palenciano G, Pérez R. Effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia [letter]. Dec 948
Martin-Cook K see Weiner MF
Martínez-Arán A see Colom F
Masand PS. Side effects of antipsychotics in the elderly. Suppl 8, 43–51
Matar MA see Lerner V
Mattia JI see Chelminski I
Mavrogiorgou P see Juckel G
Mazzarello P see Dallocchio C
McAlpine DD see Walkup JT
McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. Apr 252–260
McConville BJ see Dunayevich E
McDonald WM. Epidemiology, etiology, and treatment of geriatric mania. Suppl 13, 3–11
McElroy SL see Calabrese JR; Dunayevich E; Keck PE Jr; Shapira NA
McEnany G see Kornstein SG
McFarlane AC. Posttraumatic stress disorder: a model of the longitudinal course and the role of risk factors. Suppl 5, 15–20
McFarlane AC see Ballenger JC
McGahuey C see Gelenberg AJ
McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J, Reimherr FW, Rosenbaum JF, Beasley CM Jr. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. July 518–524
Mead S see Noordsy DL
Mehtonen O, Sogaard J, Roponen P, Behnke K, for the Venlafaxine 631 Study Group. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Feb 95–100
Melfi CA, Croghan TW, Hanna MP, Robinson RL. Racial variation in antidepressant treatment in a Medicaid population. Jan 16–21
Melkersson KI, Hulting A-L, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. Oct 742–749
Meller I see Juckel G
Meltzer HY. Introduction. Side effects of antipsychotic medications: physician's choice of medication and patient compliance. Suppl 8, 3–4
Meltzer HY. Review of Ban TA, Healy D, Shorter E (eds): *The Rise of Psychopharmacology and the Story of CINP.* Jan 65–66
Meltzer HY. Review of Tamminga CA (ed): *Schizophrenia in a Molecular Age: Review of Psychiatry, vol. 18.* Nov 877–878
Meltzer HY see Conley RR

Menza MA, Kaufman K, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. May 378–381
Menza MA see Freudenreich O
Metzger ED. Review of Rush AJ (ed): *Mood Disorders: Systematic Medication Management.* Feb 147–148
Miguel EC, do Rosário-Campos MC, da Silva Prado H, do Valle R, Rauch SL, Coffey BJ, Baer L, Savage CR, O'Sullivan RL, Jenike MA, Leckman JF. Sensory phenomena in obsessive-compulsive disorder and Tourette's disorder [CME]. Feb 150–156
Miklowitz DJ see Craighead WE
Milberger S see Schubiner H
Miller DD. Review and management of clozapine side effects. Suppl 8, 14–19
Miller MC. Review of Yehuda R (ed): *Risk Factors for Posttraumatic Stress Disorder.* July 532
Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. Nov 828–832
Miyaoka T, Seno H, Itoga M, Iijima M, Inagaki T, Horiguchi J. Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). Nov 868–871
Miyaoka T, Seno H, Maeda T, Itoga M, Horiguchi J. Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome): three case reports [letter]. Apr 299–300
Miyashiro AM see Trappler B
Modai I see Ritsner M
Moeller FG see Varner RV
Möller H-J. Are all antidepressants the same? Suppl 6, 24–28
Möller H-J see Hirschfeld RMA; Juckel G; Stübner S
Monaghan ET see Calabrese JR
Montenegro R see Hirschfeld RMA
Montgomery SA. Introduction. Understanding depression and its treatment: restoration of chemical balance or creation of conditions promoting recovery? Suppl 6, 3
Montgomery SA see Hirschfeld RMA
Montouris G see Blumer D
Montoya ID, Svikis D, Marcus SC, Suarez A, Tanielian T, Pincus HA. Psychiatric care of patients with depression and comorbid substance use disorders [CME]. Sept 698–705
Moore GJ see Manji HK
Moreno FA see Delgado PL; Gelenberg AJ
Morenz BM III. Review of Simon RI: *Bad Men Do What Good Men Dream: A Forensic Psychiatrist Illuminates the Darker Side of Human Behavior.* Aug 604–605
Mori N see Iwata Y
Moutier CY see Feifel D
Mulsant BH see Sylvester AP
Musa MN, Staneluis JM. Adverse events of fluoxetine: postmarketing compared with premarketing clinical trials [letter]. Nov 874
Nafziger AN, Bertino JS Jr, Goss-Bley AI, Kashuba ADM. Reply to Laird LK: Sexual dysfunction on fluvoxamine therapy [letter]. Jan 62–63
Najavits LM see Weiss RD
Nash JL. Review of Beitman BD, Yue D: *Learning Psychotherapy: A Time-Efficient, Research-Based, and Outcome-Measured Psychotherapy Training Program and Seminar Leader's Manual.* Nov 876–877
Nash JL. Review of Janowsky DS (ed): *Psychotherapy: Indications and Outcomes.* May 390
Nechamkin Y see Ritsner M
Nelson JC. Augmentation strategies in depression 2000. Suppl 2, 13–19
Nemeroff CB. Ever-increasing pharmacopoeia for the management of patients with bipolar disorder. Suppl 13, 19–25
Nemeroff CB. Introduction: fifty years of lithium use in the treatment of bipolar disorder. Suppl 9, 3–4
Nemeroff CB. Introduction. Norepinephrine: neurotransmitter for the millennium. Suppl 10, 3–4
Nemeroff CB see Compton MT; Gumnick JF
Neria Y see Zolomon Z
Nesvacil L see Coleman E
Newhouse PA, Krishnan KRR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM. Double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. Aug 559–568
Nierenberg AA see Fredman SJ
Nilsson ME see Beasley CM Jr; Fava M
Ninan PT, Rothbaum BO, Marsteller FA, Knight BT, Eccard MB. Placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. Jan 47–50
Nizny MM. Review of Allen JG: *Coping With Trauma: A Guide to Self-Understanding.* Dec 953–954
Nofzinger EA, Fasiczka A, Berman S, Thase ME. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. Nov 858–862
Nofzinger EA see Thase ME
Noordsy DL, Torrey WC, Mead S, Brunette M, Potenza D, Copeland ME. Recovery-oriented psychopharmacology: redefining the goals of antipsychotic treatment. Suppl 3, 22–29
Nutt DJ. Psychobiology of posttraumatic stress disorder. Suppl 5, 24–29
Nutt DJ see Ballenger JC
Ohry A see Solomon Z
Okasha A, Bishry Z, El Fiki MR, El Dawla AS, El Rasheed AH. Prodromal symptoms of relapse in a sample of Egyptian schizophrenic patients. Oct 729–736
Okayli G see Gelenberg AJ
Olfson M see Walkup JT
O'Sullivan RL see Miguel EC
Padberg F see Stübner S
Palenciano G see Martín JC
Paraherakis AM see Charney DA
Parepally H see Levine J
Parry M see Claxton A
Pauls DL see van den Heuvel OA
Pavuluri MN see Poznanski E
Peabody CD see Littrell KH
Pearlstein TB. Antidepressant treatment of posttraumatic stress disorder. Suppl 7, 40–43
Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, Yonkers KA. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. Feb 101–109
Pearlstein TB, Steiner M. Non-antidepressant treatment of premenstrual syndrome. Suppl 12, 22–27
Pearlstein TB see Steiner M
Pearson VE see Blass DM
Peindl KS see Piontek CM
Pelc I see Kornreich C
Perez J see Zanardi R
Pérez R see Martín JC
Perlick D see Rosenheck R
Perramón CT see Gómez Gómez JM[a]
Perry W see Feifel D
Peskind ER see Raskind MA
Peterson G. EMDR for treatment of PTSD [letter with reply]. Oct 784–785
Petkova E see McGrath PJ
Petrie EC see Raskind MA
Pierre JM, Gitlin MJ. Bupropion-tranylcypromine combination for treatment-refractory depression [letter]. June 450–451
Pies R. Adverse neuropsychiatric reactions to herbal and over-the-counter "antidepressants." Nov 815–820
Pies R. Free drug fraction versus free drug concentration [letter with reply]. June 449
Pincus HA see Montoya ID
Pini S see Ciapparelli A
Piontek CM, Baab S, Peindl KS, Wisner KL. Serum valproate levels in 6 breastfeeding mother-infant pairs. Mar 170–172
Piontek CM, Wisner KL. Commentary: appropriate clinical management of women taking valproate. Mar 161–163
Plakun EM, Shapiro ER. Psychodynamic psychotherapy for PTSD [letter with reply]. Oct 787–788
Plopsky I see Shamir E
Polansky M see Freeman EW
Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R. Sertraline treatment of panic disorder: response in patients at risk for poor outcome. Dec 922–927
Pollock BG see DeVane CL
Polyakova I see Lerner V
Ponizovsky A see Ritsner M
Pott RM see Brotman MA; Frye MA
Potenza D see Noordsy DL
Poznanski E, Pavuluri MN. Review of Weller EB, Weller RA, Rooney MT, Fristad MA: *ChIPS: Children's Interview for Psychiatric Symptoms.* Aug 606
Pradhan SC. Gold versus silver: the issue of functional versus symptomatic recovery in depression [letter with reply]. June 447–448
Preskorn SH see Khan A
Prosnick KP. Subtyping micromanic episodes [letter]. Feb 144–145
Quitkin FM see McGrath PJ
Rabkin R see Wagner GJ

Rader LE. Review of Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis W, Kines M (eds.): *DSM-IV Sourcebook, vol. 4.* Dec 952
Rafanelli C see Fava GA
Ramdoyal D see Steiger H
Rapaport MH see Pollack MH
Rasgon NL, Altshuler LL, Gudeman D, Burt VK, Tanavoli S, Hendrick V, Korenman S. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. Mar 173–178
Rasgon NL see Suri RA
Raskind MA, Cyrus PA. Reply to Schneider LS: Metrifonate for Alzheimer's disease patients [letter]. Mar 218–219
Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER. α_1-Adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. Feb 129–133
Ratakonda SS see Sharif ZA
Rauch SL see Miguel EC
Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. Nov 821–827
Raymond NC see Coleman E
Raza A see Sharif ZA
Reddy R see Levin H
Reeves RM. Omission of bupropion as a recommended treatment for PTSD [letter]. Oct 786
Reimherr FW see McGrath PJ
Reinares M see Colom F
Remington GJ, Kapur S. Reply to Stip E: Need for a new framework to understand the mechanism of all antipsychotics [letter]. May 388
Reynolds CF III see Thase ME
Rhoads E. Polypharmacy of 2 atypical antipsychotics [letter with reply]. Sept 678–679
Richter EM see Newhouse PA
Rickels K, Freeman EW. Prior benzodiazepine exposure and benzodiazepine treatment outcome. June 409–413
Rickels K see DeMartinis N
Riggs KW see Misri S
Rimon R see Ahokas A
Ringold AL see Koran LM
Riquier F see Zullino DF
Ritsner M, Modai I, Endicott J, Rivkin O, Nechamkin Y, Barak P, Goldin V, Ponizovsky A. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients [CME]. Nov 880–889
Rivkin O see Ritsner M
Robertson C see Duffy A
Robinson JM see Claxton A; Schmidt ME
Robinson RL see Melfi CA
Roca CA, Schmidt PJ, Rubinow DR. Reply to Soares CN: Association between premenstrual syndrome and depression [letter]. Sept 677–678
Romans SE see Elmslie JL
Ronan GF, Dreer LE, Dollard KM. Measuring patient symptom change on rural psychiatry units: utility of the Symptom Checklist-90 Revised. July 493–497
Ronis RJ. Review of Schreter RK, Scharfstein SS, Schreter CA (eds): *Managing Care Not Dollars: The Continuum of Mental Health Services.* Mar 220
Rooijmans HM see Cath DC
Roos RAC see Cath DC
Roponen P see Mehtonen O
Rosenbaum JF see Fredman SJ; McGrath PJ
Rosenheck RA, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. May 382–386
Rosenheck RA, Cramer J, Jurgis G, Perlick D, Xu W, Thomas J, Henderson W, Charney D. Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. Sept 671–676
Rosenheck RA see Druss BG
Rotenberg V see Shamir E
Rothbaum BO, Astin MC. Integration of pharmacotherapy and psychotherapy for bipolar disorder. Suppl 9, 68–75
Rothbaum BO see Ninan PT
Rothenhäusler H-B, Ehrentraut S, von Degenfeld G, Weis M, Tichy M, Kilger E, Stoll C, Schelling G, Kapfhammer H-P. Treatment of depression with methylphenidate in patients difficult to wean from mechanical ventilation in the intensive care unit. Oct 750–755
Rothschild AJ. Sexual side effects of antidepressants. Suppl 11, 28–36
Rothschild AJ see Zarate CA Jr
Rowe V see Toprac MG
Roy-Byrne PP. Reply to Weilburg J: Possible connection between panic disorder and epilepsy [letter]. Aug 602
Rubinow DR see Roca CA
Rush AJ see Toprac MG
Rüther E see Stübner S
Rynn M see DeMartinis N
Sachs GS see Calabrese JR; Guille C
Sacks MH see Goldberg JF
Sacristán JA see Gómez JC
Saine K see Weiner MF
Saiz CA see Gómez JC
Salomon RM. Review of Koran LM: *Obsessive-Compulsive and Related Disorders in Adults: A Comprehensive Clinical Guide.* Aug 606–607
Salomon RM. Review of McCullough JP Jr: *Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy (CBASP).* Sept 684
Salzman C. Review of Roth M, Huppert FA, Mountjoy CQ, Tym E: *Camdex-R: The Cambridge Examination for Mental Disorders of the Elderly, Revised.* Apr 306
Sandman AR see Sylvester AP
Saporta JA. Psychodynamic psychotherapy for PTSD [letter with reply]. Oct 787
Sarles RM. Review of Shaffer D, Lucas CP, Richters JE (eds): *Diagnostic Assessment in Child and Adolescent Psychopathology.* Sept 682–683
Savage CR see Miguel EC
Sax KW see Dunayevich E
Saxena S see Brody AL
Schatzberg AF. Clinical efficacy of reboxetine in major depression. Suppl 10, 31–38
Schatzberg AF. New indications for antidepressants. Suppl 11, 9–17
Schatzberg AF see Hirschfeld RMA
Schelling G see Rothenhäusler H-B
Schmidt ME, Fava M, Robinson JM, Judge R. Efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. Nov 851–857
Schmidt ME see Claxton A
Schmidt PJ see Roca CA
Schneider LS. Metrifonate for Alzheimer's disease patients [letter with reply]. Mar 218
Schoener E see Schubiner H
Schröter A see Juckel G
Schubiner H, Tzelepis A, Milberger S, Lockhart N, Kruger M, Kelly BJ, Schoener EP. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. Apr 244–251
Schwartz MA. Misuse of the term *phenomenology* [letter]. Apr 303–304
Scully JH Jr. Review of Hales RE, Yudofsky SC, Talbott JA (eds): *The American Psychiatric Association Textbook of Psychiatry, 3rd ed.* Apr 306
Seeman MV see Dickson RA
Seno H see Miyaoka T
Serretti A see Zanardi R
Settle EC Jr see Weihs KL
Shad MU see Khan A
Shalev AY. Measuring outcome in posttraumatic stress disorder. Suppl 5, 33–39
Shalev AY see Ballenger JC
Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for tardive dyskinesia? Aug 556–558
Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, Zisapel N. Melatonin improves sleep quality of patients with chronic schizophrenia. May 373–377
Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. May 368–372
Shapiro ER see Plakun EM
Sharif ZA, Raza A, Ratakonda SS. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. July 498–504
Sheridan MJ see Wise TN
Shiah I-S see Lam RW
Shimizu T see Takahashi H
Shon SP see Toprac MG
Shulman KI, Walker SE. Reply to Feinberg S: Clarifying the safety of the MAOI diet and pizza [letter]. Feb 145–146
Sieche A, Giedke H. Treatment of primary cranial dystonia (Meige's syndrome) with clozapine [letter]. Dec 949
Silverstone JT see Elmslie JL
Simon AE see Aubry JM
Simpson GM. Treatment of tardive dyskinesia and tardive dystonia. Suppl 4, 39–44

Slovenko R. Update on legal issues associated with tardive dyskinesia. Suppl 4, 45–57
Smeraldi E see Zanardi R
Smith DL, Wenegrat BG. Case report of serotonin syndrome associated with combined nefazodone and fluoxetine [letter]. Feb 146
Smith-Vaniz A see Zisook S
Smyth NJ, Greenwald R, de Jongh A, Lee C. EMDR for treatment of PTSD [letter with reply]. Oct 784–785
Soares CN, Cohen LS. Association between premenstrual syndrome and depression [letter with reply]. Sept 677
Soares JC, Gershon S. Psychopharmacologic specificity of the lithium ion: origins and trajectory. Suppl 9, 16–22
Sogaard J see Mehtonen O
Solomon Z, Neria Y, Ginzburg K, Dekel R, Enoch D, Ohry A. Posttraumatic residues of captivity: a follow-up of Israeli ex-prisoners of war. Jan 39–46
Sondheimer SJ see Freeman EW
Sorter MT see Dunayevich E; McConville BJ
Soto JA see Weiss RD
Soucy JP see Stip E
Soutullo CA see Keck PE Jr
Spanier CA see Frank E
Spigset O see Güzey C
Spinhoven P see Cath DC
Stahl SM. Blue genes and the mechanism of action of antidepressants [BRAINSTORMS]. Mar 164–165
Stahl SM. Blue genes and the monoamine hypothesis of depression [BRAINSTORMS]. Feb 77–78
Stahl SM. Molecular neurobiology for practicing psychiatrists, part 5: how a leucine zipper can turn on genes: immediate-early genes activate late gene expression in the brain [BRAINSTORMS]. Jan 7–8
Stahl SM. New cholinesterase inhibitors for Alzheimer's disease, part 1: their similarities are different [BRAINSTORMS]. Oct 710–711
Stahl SM. New cholinesterase inhibitors for Alzheimer's disease, part 2: illustrating their mechanisms of action [BRAINSTORMS]. Nov 813–814
Stahl SM. New drug discovery in the postgenomic era: from genomics to proteomics [BRAINSTORMS]. Dec 894–895
Stahl SM. Paying attention to your acetylcholine, part 1: structural organization of nicotinic receptors [BRAINSTORMS]. Aug 547–548
Stahl SM. Paying attention to your acetylcholine, part 2: the function of nicotinic receptors [BRAINSTORMS]. Sept. 628–629
Stahl SM. Reply to Pradhan SC: Gold versus silver: the issue of functional versus symptomatic recovery in depression [letter]. June 447–448
Stahl SM. Reply to Rhoads E: Polypharmacy of 2 atypical antipsychotics [letter]. Sept 679–680
Stahl SM. Seven habits of highly effective psychopharmacologists: overview [BRAINSTORMS]. April 242–243
Stahl SM. Seven habits of highly effective psychopharmacologists, part 2: begin with the end in mind [BRAINSTORMS]. May 327–328
Stahl SM. Seven habits of highly effective psychopharmacologists, part 3: sharpen the saw with selective choices of continuing medical education programs [BRAINSTORMS]. June 401–402
Stahl SM. Seven habits of highly effective psychopharmacologists, part 4: developing and implementing the vision [BRAINSTORMS]. July 464–465
Staneluis JM see Musa MN
Stapf DM see Frank E
Stauffer VL see Kinon BJ
Steiger H, Leonard S, Kin NMK, Ladouceur C, Ramdoyal D, Young SN. Childhood abuse and platelet tritiated-paroxetine binding in bulimia nervosa: implications of borderline personality disorder. June 428–435
Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. Suppl 12, 17–21
Steiner M see Pearlstein T
Stewart JW see McGrath PJ
Stip E, Liddle PF, Soucy JP. Need for a new framework to understand the mechanism of all antipsychotics [letter]. May 387–388
Stoll C see Rothenhäusler H-B
Stoner SC see Jones MT
Stotz G see Juckel G
Stout AL see Pearlstein TB
Strakowski SM see Dunayevich E; Keck PE Jr
Straumanis JJ. Review of DuPont RL: *The Selfish Brain: Learning From Addiction.* June 454
Strauss MJ see Sullivan EM
Stübner S, Padberg F, Grohmann R, Hampel H, Hollweg M, Hippius H, Möller H-J, Rüther E. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. Aug 569–574
Su M-H see Lane H-Y; Le M-L
Suarez A see Montoya ID
Sullivan EM, Griffiths RI, Frank RG, Strauss MJ, Herbert RJ, Clouse J, Goldman HH. One-year costs of second-line therapies for depression. Apr 290–298
Sullivan G see Gorman JM
Suppes T, Dennehy EB, Gibbons EW. Longitudinal course of bipolar disorder. Suppl 9, 23–30
Suppes T see Calabrese JR
Suri RA, Altshuler LL, Rasgon NL, Calcagno JL, Frye MA, Gitlin MJ, Hwang S, Zuckerbrow-Miller J. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. Dec 942–946
Suzuki H see Wada K
Svetlik DA see Weiner MF
Svikis D see Montoya ID
Swann AC see Calabrese JR; Varner RV
Sylvester AP, Mulsant BH, Chengappa KNR, Sandman AR, Haskett RF. Use of electroconvulsive therapy in a state hospital: a 10-year review [CME]. July 534–539
Szegedi A see Benkert O
Takahashi H, Higuchi H, Shimizu T. Severe lithium toxicity induced by combined levofloxacin administration [letter]. Dec 949–950
Takei N see Iwata Y
Talamantes M see Katerndahl DA
Tam EM see Lam RW
Tanavoli S see Rasgon NL
Tanguay PE. Review of Siegel DJ: *The Developing Mind: Toward a Neurobiology of Interpersonal Experience.* July 531
Tanielian T see Montoya ID
Taylor LH, Kobak KA. Open-label trial of St. John's wort (*Hypericum perforatum*) in obsessive-compulsive disorder. Aug 575–578
Terao T, Ikemura N. SSRI-TCA combination in the treatment of resistant depression [letter]. July 529
Teter CJ, Early JJ, Frachtling RJ. Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution [letter]. Nov 872–873
Thase ME. Treatment issues related to sleep and depression. Suppl 11, 46–50
Thase ME. Treatment of severe depression. Suppl 1, 17–25
Thase ME, Friedman ES, Fasiczka AL, Berman SR, Frank E, Nofzinger EA, Reynolds CF III. Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. July 466–472
Thase ME see Nofzinger EA
Thomas J see Rosenheck R
Thompson CE see Raskind MA
Thompson TL II. Review of Cunningham Owens DG: *A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs.* Nov 878
Thurstone CC, Alahi P. Possible case of quetiapine withdrawal syndrome [letter]. Aug 602–603
Thyrum PT see McConville BJ
Tichy M see Rothenhäusler H-B
Tigges P see Juckel G
Tinker-Wilson SA see Figley CR
Tohen M see Zarate CA Jr
Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. Suppl 9, 97–104
Toprac MG, Rush AJ, Conner TM, Crismon ML, Dees M, Hopkins C, Rowe V, Shon SP. Texas Medication Algorithm Project patient and family education program: a consumer-guided initiative. July 477–486
Torrey WC see Noordsy DL
Trappler B, Miyashiro AM. Bupropion-amantadine–associated neurotoxicity [letter]. Jan 61–62
Tsuang J, Liberman RP. Review of Johnstone E, Humphreys M, Lang F, Lawrie S, Sandler R: *Schizophrenia: Concepts and Clinical Management.* Mar 221–222
Tzelepis A see Schubiner H
Valle RD see Miguel EC
van den Heuvel OA, van de Wetering BJM, Veltman DJ, Pauls DL. Genetic studies of panic disorder: a review. Oct 756–766
van de Wetering BJM see Cath DC; van den Heuvel OA
van Woerkom TCAM see Cath DC

Varner RV, Chen YR, Swann AC, Moeller FG. Brief Psychiatric Rating Scale as an acute inpatient outcome measurement tool: a pilot study. June 418–421
Varnes KM see Vernon LT
Venlafaxine 631 Study Group see Mehtonen O
Vernon LT, Fuller MA, Hattab H, Varnes KM. Olanzapine-induced urinary incontinence: treatment with ephedrine [letter]. Aug 601–602
Versiani M see Hirschfeld RMA
Verwey B, Eling P, Wientjes H, Zitman FG. Memory impairment in those who attempted suicide by benzodiazepine overdose [CME]. June 456–459
Vieta E see Colom F
von Degenfeld G see Rothenhäusler H-B
Wada K, Yamada N, Suzuki H, Lee Y, Kuroda S. Recurrent cases of corticosteroid-induced mood disorder: clinical characteristics and treatment. Apr 261–267
Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. June 436–440
Wagner PG, Welton SR, Hammond CM. Gastrointestinal adverse effects with divalproex sodium and valproic acid [letter]. Apr 302
Waikar MV see Brooks JO III
Wakefield D see Hickie IB
Wakhlu S see Blumer D
Walker SE see Shulman KI
Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S. Patients with schizophrenia at risk for excessive antipsychotic dosing. May 344–348
Wat KHY see Leung C
Weihs KL, Settle EC Jr, Batey SR, Houser TL, Donahue RMJ, Ascher JA. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. Mar 196–202
Weilburg JB. Possible connection between panic disorder and epilepsy [letter with reply]. Aug 602
Weiner JS. Review of Ford CV: *Lies! Lies!! Lies!!! The Psychology of Deceit.* Aug 604
Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. July 487–492
Weinstein D. Review of Mondimore FM: *Bipolar Disorder: A Guide for Patients and Families.* Oct 789–790
Weis M see Rothenhäusler H-B
Weiss RD, Griffin ML, Greenfield SF, Najavits LM, Wyner D, Soto JA, Hennen JA. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. May 361–367
Weissman MM. Social functioning and the treatment of depression. Suppl 1, 33–38
Weissman SH. Review of Ebert MH, Loosen PT, Nurcombe B (eds): *Current Diagnosis and Treatment in Psychiatry.* Dec 953
Weissman SH. Review of Gabbard GO (ed): *Countertransference Issues in Psychiatric Treatment (Review of Psychiatry Series, vol. 18).* June 452
Weizman A see Shamir E
Welton SR see Wagner PG
Wenegrat BG see Smith DL
White CN see Fredman SJ
Wientjes H see Verwey B
Wilkinson LA see McConville BJ
Williams SM see Elmslie JL
Wilson AJ see Hickie IB
Wise TN, Sheridan MJ. Venlafaxine versus sertraline for major depressive disorder [letter]. Nov 873–874
Wisner KL see Piontek CM
Wolkow R see Pollack MH
Wonodi I see Lin K
Woods SW. Economic burden of bipolar disease. Suppl 13, 38–41
Wright JM see Hickie IB
Wu S-T see Lane H-Y
Wu W see Rosenheck R
Wyler A see Blumer D
Wyner D see Weiss RD
Yamada N see Wada K
Yank G. Review of American Society of Clinical Psychopharmacology, Inc.: *Model Psychopharmacology Curriculum for Psychiatric Residency Programs, Training Directors, and Teachers of Psychopharmacology.* Dec 952–953
Yatham LN see Lam RW
Yeh C see McConville BJ
Yehuda R. Biology of posttraumatic stress disorder. Suppl 7, 14–21
Yonkers KA see Pearlstein TB
Young SN see Steiger H
Zajecka JM. Clinical issues in long-term treatment with antidepressants. Suppl 2, 20–25
Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. Jan 26–29
Zapatel J see Zarate CA Jr
Zarate CA Jr. Antipsychotic drug side effect issues in bipolar manic patients. Suppl 8, 52–63
Zarate CA Jr. Reply to Wagner PG: Gastrointestinal adverse effects of divalproex sodium and valproic acid [letter]. Apr 302–303
Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. Mar 185–189
Zarate CA Jr, Tohen M. Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study. Jan 33–38
Zentner L see Gelenberg AJ
Zimmerman M see Chelminski I
Ziprasidone I.M. Study Group see Brook S
Zis AP see Lam RW
Zisapel N see Shamir E
Zisook S, Chentsova-Dutton YE, Smith-Vaniz A, Kline NA, Ellenor GL, Kodsi AB, Gillin JC. Nefazodone in patients with treatment refractory posttraumatic stress disorder. Mar 203–208
Zitman FG see Verwey B
Zuardi AW see Hallak JEC
Zuckerbrow-Miller J see Suri RA
Zullino DF, Riquier F. Venlafaxine and vivid dreaming [letter]. Aug 600